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ABSTRACT
HIV, hepatitis B and C virus (HBV, HCV) are three of the most common
blood-borne infections and they continue to be a major public health problem in the
United States (US) and globally. It is not well understood if maternal infection with either
HBV or HCV has an adverse impact on pregnancy outcomes as findings from previous
studies have provided some mixed results. The overall goal of this study was to assess the
risk of preterm birth, low birth weight (LBW), small for gestational age (SGA) and
admission into neonatal intensive care unit (NICU) for babies born to HBV- and HCVinfected women. To this end, our objectives were to 1) describe the epidemiology of
HBV and HCV and their co-infection with HIV in South Carolina (SC), 2) assess the
spatial distribution of HCV infection in SC, and 3) estimate the risk of preterm birth,
LBW, SGA, NICU admission in babies born to hepatitis-infected mothers. Linked data
from multiple sources for years 2004 to 2011 was utilized and descriptive statistics,
Bayesian spatial and logistic regression analyses were conducted to evaluate the
objectives of the study. Results revealed substantial variation in the epidemiology of
these infections among females in SC to include an emerging epidemic of HCV
infections among young white females. The spatial analysis identified Charleston,
Darlington, Florence, Georgetown, Greenville, Horry, Oconee, McCormick and Richland
counties as high-risk counties for HCV infection. Lastly, results from the logistic
regression analysis supported the fact that low birth weight is independently associated
with HCV infection during pregnancy, specifically, newly diagnosed mothers. Our
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findings are useful for providers to advise infected expectant mothers on the potential risk
to their baby. Local and state public health officials can also use these data for taking
further public health action and make informed decisions on how to allocate limited
resources to help prevent and reduce the spread on HCV and HBV infections within the
state.
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CHAPTER 1
BACKGROUND AND OBJECTIVES
1.1 Background
Human Immunodeficiency Virus (HIV), hepatitis B and C virus (HBV, HCV) are three
of the most common blood-borne infections and are a major public health problem in the
United States (US) and globally. Collectively, they cause significant morbidity and
mortality from chronic liver diseases, hepatocellular carcinoma (HCC) and opportunistic
infections among infected individuals 1-5. According to the World Health Organization
(WHO), approximately 2 billion people worldwide are infected with HBV and more than
240 million of these people live with chronic HBV infection 6. Likewise, HCV is
widespread; the disease kills 350,000 people per year (1% of all deaths worldwide) and
there are an estimated150 million people that are chronically infected 7, 8.
1.1.1 Epidemiology of HBV, HCV and HIV Co-infection
Hepatitis simply refers to inflammation of the liver. HBV and HCV infection
primarily affects the liver and is usually symptomless for decades. Acute infection with
HBV or HCV is short-term (6 months) whereas chronic infection is a lifelong illness that
occurs if the infection remains in the body beyond six months. If untreated, the virus
causes considerable damage to the liver that can lead to cirrhosis, liver cancer and death.
Patterns of HBV infection vary worldwide and its geographic distribution to the
prevalence of certain risk factors for HBV infection. In regions of high endemicity such
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as Asia and sub-Saharan Africa where HBV prevalence is greater than 8% 9, major risk
factors for HBV infection include perinatal transmission, blood transfusions and sexual
contact. On the contrary, in regions of low endemicity, intravenous drug use is considered
to be leading risk factor for HBV infection. Global variation in HCV prevalence is also
evident, as the disease tends to be higher in developing countries, especially those in
North Africa. For instance, with nearly 15% of population infected, Egypt has one of
worst affected populations in the world 8, 10.
In the US, a region where HBV and HCV infections are considered to be low in
prevalence, the Centers for Disease Control and Prevention (CDC) reported 10, 515 new
sentinel cases of chronic HBV and 25,974 new sentinel cases of chronic HCV in 2010. It
is believed that between 1.25 million and 2 million individuals are infected with HBV in
the US, more than 50% of which are of Asian ethnicity 11, 12. When we consider
incarcerated, homeless and active military persons otherwise not found in populationbased surveys, the numbers for those affected by HBV and HCV is significantly higher.
One study conservatively cited 5.2 million as the true number of persons living with
HCV within the US 13. Within the state of South Carolina (SC), surveillance data for
HBV and HCV infections are routinely reported to the Division of Acute Disease
Epidemiology (DADE). Between 2004 and 2008, an average of 661 reports of chronic
HBV and nearly 20,000 cases of chronic HCV was reported to DADE between the years
of 2000 and 2005 14. For these same periods, 601 cases of acute HBV and 70 cases of
acute HCV infections were reported to DADE. It is worthy to note that because new
HCV case are usually asymptomatic, acute HCV infections are rarely identified or
reported.

2

Since its discovery in 1981, at least 60 million people have been infected with
HIV and nearly 25 million have died of AIDS 15. The devastating effect of this pandemic
continues to pose a significant public health threat particularly in developing countries;
nevertheless, in developed countries where there is increased access to highly active
antiretroviral treatment (HAART) for disease management, HIV is no longer the death
sentence it used to be. In fact, when detected early, the life expectancy of an HIV infected
individual can be restored to near normal through successful HAART treatment. For this
reason, HIV is now considered a manageable chronic condition and HIV infected
individuals on continued therapy have an improved quality of life and are able to live
long productive lives 16, 17. HIV infected persons are disproportionately affected by viral
hepatitis: As of 2009, an estimated 1.2 million persons aged 13 and older residing in the
US are living with a diagnosis of HIV infection 18. Of these, approximately 20-30% are
also infected with HCV, while, at least 10% of these HIV-infected individuals are coinfected with HBV 19, 20. HIV-HBV and HIV/HCV co-infections are highly prevalent
because of shared risk factors and common routes of transmission 2, 3, 21. HIV modifies
the natural history of HCV and HBV disease among co-infected individuals; They are
more likely to develop chronic hepatitis 22 and have an increased risk of liver-related
mortality and morbidity and suffer life-threatening complication beyond those caused by
either infection alone 23, 24.
1.1.2

HBV, HCV and HIV Co-infection in Pregnant Women
Within the obstetric population, HBV, HCV and HIV co-infections also affect a

significant number of pregnant women. Worldwide, HCV infection in pregnant women
varies from 1% to 8% 25; in the US, the prevalence of HBV infection among women of
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childbearing age is estimated to be 0.7% 26, while that of HCV is estimated to be around
1% 27, even though this number is increasing. A recent study in Florida reported an
increase in the prevalence of HBV infection among pregnant women from 65.4 to 123.5
per 100,000 births between 1998 and 2007; the same increase was also reported for HCV
infection in pregnant women 28. In high endemic regions such as sub-Saharan Africa,
HIV is associated with being HBV- or HCV-positive 29 and among pregnant women,
higher HIV co-infection rates have been reported to range from 4.1% -8.9% for HBV and
1.8%-2.1% for HCV 30-33. In the only known cohort of HIV-infected pregnant women
studied in the US, a 1.5% and 4.9% prevalence was reported for HBV-HIV and HCVHIV infections respectively 34. Furthermore, Salihu et al. observed an increased risk of
HBV and HCV co-infections among HIV/AIDS women when compared to their HIVnegative counterparts in his study 28.
In the absence of contaminated blood transfusions, sexual transmission and
intravenous drug use, a substantial proportion of all chronic HBV cases worldwide are
attributed to perinatal transmission of HBV. In spite of vaccine availability, infected
pregnant women remain an important source for HBV chronic infection as children who
acquire the infection at birth through mother-to-child transmission (MTCT) have up to a
90% risk of becoming chronic cases themselves 35. Therefore, the CDC recommends
routine screening for HBV at the time of the first prenatal visit with each pregnancy
regardless of vaccination or previous testing 36.
On the contrary, there is no current vaccine for HCV and maternal screening
during prenatal visits is risk-based and not universal. Similar to HBV, MTCT of HCV is
a major source of new infections among young children and 80% of perinatal cases that
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remain HCV RNA-positive after age three develop into chronic HCV cases 37, 38. In HIV
infected pregnant women, maternal co-infection with viral hepatitis facilitates the
transmission of HBV or HCV to newborns 39-42 and children born to co-infected mothers
have an increased risk of progressing to chronic forms of the disease. Hence, the
management of HBV and HCV disease during pregnancy, especially among HIV positive
mothers who are co-infected with viral hepatitis remains an important public health issue
as reducing perinatal transmission of these diseases is crucial to reducing the global
burden of these diseases 43, 44.
1.2 Rationale
There remains a gap in knowledge in how HBV and HCV infection affects pregnancy
outcomes. In reality, it is not well understood if mono infections with HBV or HCV have
an adverse impact on pregnancy and perinatal outcomes. Previous studies (see Appendix
A) from a variety of countries that have investigated this issue have reported inconsistent
results.
Majority of the studies that were reviewed used a case-control study design,
which provides marginal evidence for establishing a “causal relationship” between
maternal HBV or HCV carrier status and any of the adverse pregnancy or perinatal
outcomes studied. Furthermore, methodological concerns and limitations noted in these
studies further weaken the epidemiological evidence that these studies present. In
particular, residual confounding, small and non-representative samples of cases,
information and selection bias is likely to have affected the validity of these studies and
consequently biased the conflicting results found.
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For HBV infected pregnant women, a few studies 45-47 have shown an increased
risk for preterm delivery, congenital abnormalities and gestational diabetes while others
studies 44, 48 found no such differences. Similarly, studies on HCV infected pregnant
women 44, 46, 49, 50 found that the maternal HCV status was associated with a higher risk of
low birth weight, preterm delivery, congenital anomalies, cesarean delivery, gestational
diabetes and perinatal mortality. In contrast, other studies 51-54 did not detect significant
differences in risks associated with these same outcomes (Appendix A).
Across all studies, hepatitis B surface antigen (HBsAg) assay, an administered
test used to check for the presence of HBV antibodies, was the measure used to determine
HBV exposure status. Being HBsAg positive only indicates active infection, which could
mean that the mother has either a chronic or acute infection. Thus, without any
information on hepatitis B core antibody (anti-HBc) for the study participants that tested
HBsAg positive at the time of pregnancy, it is hard to distinguish between acute and
chronic infection status. Moreover, HBsAg provides no indication of past infection or
previous infection with hepatitis B. In the same way, an anti-HCV test only indicates
exposure to HCV virus and does not distinguish between someone with an active or
previous HCV infection; therefore exposure misclassifications error with HBV or HCV
status may bias the true risk estimates of pregnancy-related outcomes in this population.
Of equal importance, residual confounding from previous or past exposure to HBV
infection, which may have been treated or cleared at the time of pregnancy was not
accounted for in confounders adjusted for in these studies.
Residual or uncontrolled confounding due to poor and imprecise measurement of
confounding variables was also a potential problem in these studies. Most importantly,
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the measurements of drug and alcohol use, also strongly related to poor pregnancy
outcomes, were not consistently accounted for across all studies. Since drug and alcohol
abuse is often underreported during pregnancy, it is likely that residual confounding from
these variables occurred and consequently impacted the study results. Furthermore,
without adequate control for confounders such as drug and alcohol use, the magnitude of
any association between HCV/HBV exposure and pregnancy would be inaccurately
quantified, especially if such an association is small. Likewise, the effect of HCV and
HBV viral load during pregnancy was not accounted in all the studies. HCV/HBV viral
load provides information on the severity of the disease. There is reason to believe that,
like HIV, women with a well-controlled HCV/HBV viral load during pregnancy may
have better outcomes than women with high viral loads during pregnancy.
The highly selective samples used in some studies 47, 51, 52, 55-57 may have reduced
the generalizability to other populations. Even though a few of the studies used
population-based samples the remaining studies from other countries were recruited from
specialty clinics or single-sites (Appendix A). The sample sizes in these hospital-based
cohorts were often small (< 50 cases) and therefore, had insufficient power to detect
associations between pregnancy-related outcomes and HBV or HCV carrier status
(Appendix A). Additionally, cases differed greatly on a number of characteristics from
the selected controls, which reduced their comparability to each other. To illustrate, in a
case-control study 52 conducted in Ireland, the birth outcomes of 36 Rhesus negative
women infected with HCV (cases) were compared to Rhesus positive women without
HCV infection (controls). The authors 52 reported no difference in risk for pre-term
delivery. Lack of comparability between the cases and controls is a source of bias and
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may have biased the risk estimate towards the null. In another case-control study 49 of
HBV and HCV infected pregnant women in Israel, the authors combined HBV and HCV
cases in their analysis and found that HBV or HCV carrier status was associated with an
increased risk for pre-term delivery, perinatal mortality, congenital malformations and
low birth weight. It is therefore difficult to ascertain whether the observed risk is
attributable to HCV or HBV infection.
Lastly, in population-based studies where samples from birth certificates were
linked to hospital discharge data, the statistical analysis did not account for withinwoman (within-subject) correlations resulting from clusters of women who had more
than one live birth during the study period. In instances where observations are not
independent, a more complex regression model such as generalized estimating equations
(GEE) or a mixed model approach is needed to account for the correlations within
subjects. Logistic regression, which assumes independent observations, was incorrectly
used to analyze the results presented in these studies. Consequently, the standard errors
obtained are incorrect and the variability is often overestimated leading to inappropriate
inferences and inflated P values 58, 59.
Because large numbers of hepatitis infected pregnant women are never identified,
practice patterns for optimal management of pregnancies from infected HBV or HCV
mothers are yet to be established. Findings from this study can be used to enhance and
provide targeted prenatal care services that could significantly improve the quality of
birthing outcomes for the baby and mother. Furthermore, a better understanding of how
HCV or HBV impacts pregnancy outcomes could lead to useful prevention strategies.

8

That aside, it is also important to study the magnitude of chronic HCV and HBV
infection among pregnant populations and HIV/AIDS population in the state of SC,
possibly representing conditions in the southern part of the US. A detailed description of
the disease burden within the prenatal population of SC will provide an impetus for
prioritizing, and creating targeted interventions. The resulting information is not only
useful for health planning and disease control, but it can also be used to improve maternal
and child health locally and nationally at the population level. Additionally, it is
important to know the geographic and spatial distribution of these infections within the
state would provide valuable knowledge for health department personnel, policy makers
and health managers to plan and implement interventions and allocate limited health
resources.
The primary objective of the proposed project therefore is in threefold focused on
the descriptive epidemiology and spatial distribution of these infections in SC as well as
an analytic aspect aimed at elucidating how maternal HBV or HCV status during
pregnancy affects birth outcomes.
1.3 Objectives
Descriptive epidemiologic study
1. To describe the epidemiology of HBV or, HCV infection and HIV-hepatitis coinfection among reported female cases in SC between years 2004 and 2011.
Research Question 1.1: What is the prevalence of HBV mono-infection and
HBV/HIV co-infection in reported females cases in SC?
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Research Question 1.2: What characteristics are associated with HBV monoinfection and HBV/HIV co-infection in reported female cases in SC?
Research Question 1.3: What is the extent of data agreement between the data
sources (electronic birth registry and disease surveillance data) used to capture
maternal hepatitis B surface antigen (HBsAg) infection status during
pregnancy?
Research Question 1.4: What is the prevalence of HCV mono-infection,
HCV/HBV and HCV/HIV co-infection in reported female cases in SC?
Research Question 1.5: What are the demographic characteristics, patterns of
CD4+ T-lymphocyte count (CD4), sequence of virus diagnosis and risk factors
at time of HIV infection among HCV-positive and HCV/HIV positive females
in SC?
Geospatial study
2. To assess the spatial distribution of HCV-infected female cases in SC between
years 2004 and 2011.
Research Question 2.1: Given the counts of HCV cases reported in each
county, do any of the counties have higher counts of disease than what is
expected?
Research Question 2.2: What are the demographic characteristics of those areas
in SC that exhibit high risks for HCV infection?
Research Question 2.3: Is high drug use activity and other socio-economic or
environmental factors explain the observed risks for HCV infection in these
counties?
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Associations of HBV and HCV with birth outcomes
3. To estimate the association between maternal HBV or HCV status and selected
pregnancy outcomes for singleton births that occurred in SC between 2004 and
2011.
Research Question 3.1: Is being HBV- or HCV-positive during pregnancy
associated with an increased risk for the following adverse birth outcomes:
preterm birth, low birth weight, small for gestational age and neonatal intensive
care admission?
Research Question 3.2: What is the association of an adverse birth outcome
with recently diagnosed infected pregnancies and pregnancies from mothers
who are chronic carriers?
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CHAPTER 2
HEPATITIS B VIRUS (HBV) AND HBV/HIV CO-INFECTION AMONG REPORTED
FEMALE CASES IN SOUTH CAROLINA
2.1 Abstract
The aim of this study was to characterize the burden of hepatitis B virus (HBV) and
human immunodeficiency virus (HIV) co-infection, demographic characteristics and the
order of HBV/HIV virus diagnosis in women in South Carolina (SC). Additionally, for
maternal hepatitis B surface antigen positive (HBsAg+) cases, we evaluated the data
agreement between surveillance data for HBV and HIV, linked to birth registry data for
years 2004 to 2011. A total of 2,245 female cases of HBV (confirmed and probable) were
included. Of these, 1 918 (85%) were chronic HBV (cHBV) cases, 325 (15%) were acute
HBV (aHBV) cases and 2 were perinatal cases. Chronic HBV/HIV co-infection made up
4.2% of all cases. HIV was diagnosed first in 74% of cHBV/HIV cases with a median
time to HBV diagnosis of 9 years (range, 2-21). Black women represented 78% of all
cHBV/HIV cases and heterosexual contact was the most commonly reported mode for
HIV transmission (58%). At the time of HIV diagnosis, most cases had HIV viral load
counts >100,000 copies/mL and lived in urban areas of the state. Agreement measures for
HBsAg+ women reported to surveillance and birth registry records were moderate:
Cohen’s Kappa = 0.49 (95% CI= 0.44-0.54); percent positive agreement = 49%. An
increase in efforts to improve screening, reporting and prevention especially among black
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women is warranted. Also, reports to disease surveillance of infections diagnosed during
prenatal screening needs to be improved.
2.2 Introduction
Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) constitute a
major public health concern globally as both infections are a significant cause of
morbidity and mortality worldwide. HBV, a leading cause of acute and chronic liver
disease, is responsible for approximately 1 million international deaths annually 6, 60. It is
estimated that approximately one third of the world’s population (over two billion
individuals) have been infected with HBV, and 350 million of these individuals are
chronically infected. In the United States (US), a country of low HBV endemicity,
approximately 19 000 new cases of acute HBV infections occurred in 201161; moreover,
it is believed that between 1.25 and 2 million individuals are chronically infected with
HBV 62, 63.
Comparatively, HIV-infection is among the top ten causes of death worldwide,
accounting for over 1.5 million deaths annually 64. Since its discovery in 1981, at least 60
million individuals have been infected and nearly 25 million have died of acquired
immunodeficiency syndrome (AIDS) 15. In the post-HAART (highly active antiretroviral
treatment) era, AIDS-related deaths have continued to decline in developed countries and
presently, there are more individuals living with HIV as a chronic condition than ever
before. Based on a 2011 global estimate, there are 37 million individuals living with HIV
65

.
Among unvaccinated HIV-infected individuals, HBV co-infection with HIV is

prevalent because of shared risk factors and common routes of transmission. Of the 1.3
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million individuals living with an HIV diagnosis in the US as of 2011, at least 10% were
co-infected with HBV 20. Among co-infected individuals, HIV negatively impacts the
natural history of HBV disease. These individuals are more likely to develop chronic
hepatitis 22 and progress to cirrhosis, have an increased risk of liver-related mortality and
morbidity and suffer life-threatening complications beyond those caused by either
infection alone 24.
The burden of HBV mono-infection or co-infection with HIV among US women
is not well known 66 especially in antenatal populations and among women of
childbearing age. More precisely, national estimates 12, 67 of HBV prevalence in US
women are based on data from the National Health and Nutrition Examination Survey
(NHANES) which excludes high risk populations such as incarcerated and homeless
persons or minority populations such as Asians and Pacific Islanders in which the disease
is most common 68. This population-based study overcomes these limitations by
including all women, especially those at high risk for disease acquisition.
The aim of this investigation is twofold. First, to describe the characteristics
associated with HBV mono-infection and HBV/HIV co-infection (demographics, timing
of infection, risk factors and clinical characteristics). Second, to assess the extent of
agreement between two data sources (electronic birth registry and disease surveillance
data) used to capture maternal hepatitis B surface antigen (HBsAg) infection status
during pregnancy.
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2.3 Methods
Data sources
Three data sources were used for this study: the South Carolina (SC) Health
Electronic Surveillance System (CHESS) and the enhanced HIV/AIDS Reporting System
(eHARS) both obtained from the SC Department of Health and Environmental Control
(DHEC), and the live birth registry records obtained from the SC Budget and Control
Board, Office of Research and Statistics (ORS). The CHESS database containing all the
HBV (probable or laboratory-confirmed) cases was linked to eHARS database that
contains HIV case reports. The resulting dataset was then linked to the birth registry
records to assess agreement for HBsAg-positive cases reported to CHESS. Institutional
Review Boards for the SC DHEC, the University of SC Office of Research Compliance
and the ORS Data Oversight Committee approved this study.
CHESS data
Acute and chronic HBV infection is mandated by SC law to be reported to DHEC
and is recorded in CHESS. This database is part of the Centers for Disease Control and
Prevention (CDC) National Electronic Disease Surveillance System (NEDSS), which has
been used for disease surveillance and reporting since 2004 69. This web-based
infrastructure is a passive surveillance system. Following the submission of an initial
report and case investigation by the local public health department, a DHEC specialist
reviews the investigation to make sure it meets the surveillance case definitions as set
forth by the CDC guidelines. A confirmed acute HBV infection was defined as the
presence of immunoglobulin M antibody to hepatitis B core antigen (IgM anti-HBc) or
HBsAg positive and evidence of an acute illness with discrete onset of symptoms and
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jaundice or elevated serum aminotransferase levels (ALT). A probable acute HBV case
was defined as a positive result for either IgM anti-HBc or HBsAg with missing or
incomplete clinical information. A confirmed case of chronic HBV infection was defined
as HBsAg positive, HBV DNA positive, or hepatitis B e antigen (HBeAg) positive two
times at least six months apart. Persons testing positive for a single HBsAg or HBV DNA
or HBeAg test with either a negative IgM anti-HBc or no IgM anti-HBc test reported
were defined as probable chronic HBV cases. CHESS data for cases occurring from
January 2004 to December 2011 included the following information: reported age, race,
public health region, year case was reported, case investigation status (probable or
laboratory confirmed), case zip code, reason for HBV testing and date of diagnosis.
Enhanced HIV/AIDS Reporting System (eHARS)
Since 1986, HIV infection has been reportable by name to SC DHEC and
recorded in eHARS. The quality of data from eHARS exceeds the CDC minimum
standards on reporting timeliness and completeness 70. The eHARS data for SC female
cases who were diagnosed with HIV infection or presumed to be living with HIV/AIDS
by December 2011 included the following: date of birth, race/ethnicity, date of HIV
diagnosis, residence at time of diagnosis (rural or urban), risk behavior, HIV/AIDS
disease stage, source of report, CD4+ T-cell counts and HIV viral load values and dates
of report.
Birth registry data
To determine maternal HBsAg sero-status, the CDC recommends routine testing
for all pregnant women during each pregnancy, if at risk for infection during pregnancy
and at the time of admission for delivery if a prenatal HBsAg test result is not available
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71

. In 2004, the SC’s birth certificate was revised to include maternal HBV and HCV

infection present/and or treated during pregnancy. For the purpose of this study, the
following information was used for records of all singleton live births that occurred for
SC women between the ages of 15 and 49, during January 2004 to December 2011
inclusive: demographic variables of the mother and infant, date of last menstrual period
(LMP), pregnancy history, risk factors and infections present during pregnancy, birth
weight, gestational age and Apgar score of newborn, breastfeeding, presence of
congenital anomalies and fetal death.
Data linkage
ORS created a unique identifier that includes the name, date of birth, social
security number, gender and race of each case and this unique identifier was used to link
cases across multiple data sets. Figure 2.1 describes the data linkage process used to
obtain the final datasets used for analysis. Starting with CHESS data to identify a
reference group, female records of confirmed and probable HBV cases that were reported
in SC from 2004 to 2011 was linked to eHARS. This step identified the proportion of
female cases that were co-infected with HIV. The initial result was HBV and HBV/HIV
infected female cases reported in SC during the study period with characteristics relevant
to HIV infection status.
Subsequently, the resulting data set was linked to the ORS integrated system to
obtain live birth records over the stated study period. This step further identified women
who were recorded as being HBsAg-positive during their pregnancy and provided
additional data on the proportion of HBV and HBV/HIV infected cases that had live
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births during the study period. Trained statisticians from DHEC and ORS performed the
record linkage and the final data set contained no personal identifiers.
Statistical analysis
We compared demographic and clinical variables from CHESS and eHARS
across groups of women identified as being co-infected with HIV (cHBV/HIV) or monoinfected with either acute (aHBV) or chronic HBV (cHBV). For HBV cases with missing
date of diagnosis, the date case was reported to CHESS was used as an approximate
diagnosis date instead. Descriptive statistics such as proportions and means were
employed to summarize the relative frequencies of HBV and HBV/HIV infected cases
within the entire sample. The Chi-square (χ2) statistic was used to determine if frequency
distributions of demographic characteristics differed significantly between disease
groups. Continuous data were expressed as median and range or interquartile range (IQR)
as appropriate and the Kruskal-Wallis test was used for comparison.
We used Cohen’s kappa and positive agreement (Pa) 72 to investigate the degree of
concordance between HBsAg-positive cases identified through birth certificate data and
those reported through CHESS. This part of our analysis was restricted to birth data from
women who had only one singleton pregnancy for the entire study period, as it was
difficult to ascertain accurate counts from women who had had more than one singleton
pregnancy over the study period. It was particularly challenging in scenarios where
women with more than two pregnancies had one pregnancy reported to CHESS during
which the mother was identified as being HBsAg-positive but for the remaining
pregnancies she was either identified as being HBsAg-negative or her HBsAg-positive
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status was not reported to CHESS. All statistical analysis were performed using SAS
(version 9.3, SAS institute, Inc.) and DAG_Stat 73.
2.4 Results
During the 8-year study period, a total of 2,245 positive HBsAg notifications
consistent with either chronic or acute HBV infection from 2,223 females were reported
to CHESS (Figure 2.2). Of the 2,245 cases reported, 1,918 (85%) were chronic HBV
(cHBV) infections and 325 (15%) were acute HBV (aHBV) infections. Only two
perinatal cases of HBV were reported for the entire study period. Ninety four percent of
aHBV were classified as confirmed cases compared to only 65% of cHBV cases met the
clinical definition for a confirmed case.
HBV mono-infection individual characteristics
There were 1,754 cHBV and 295 aHBV reports from mono-infected women
(Table 2.1). Approximately 281 prevalent cases of HBV were reported each year. Among
women with available race information, Black and White women represented 20% and
12% of all HBV cases reported during the study period. Both groups of women were
relatively young at the time of HBV notification (aHBV: median age=41 years; cHBV:
median age=37 years). Geographically, over the 8-year period, the northeastern region
(Pee Dee) of the state reported the largest proportion of aHBV (31%) whereas the central
region (Midlands) of the state reported the largest proportion of cHBV (28%) cases.
HBV/HIV co-infection
Of the 1,918 cHBV cases reported, 164 (8.6%) were co-infected. Among coinfected cases, 83 (50.6 %) cases were co-infected with hepatitis C virus (HCV) and 81
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(49.4 %) cases were co-infected with HIV (cHBV/HIV). The results of only the
HBV/HIV cases are reported here (Tables 2.1 and 2.2). Black women represented 78%
of all the cHBV/HIV cases identified and the median age at cHBV notification was 42
years (range 21-63). Heterosexual contact was the most commonly (57%) reported mode
for HIV transmission followed by injecting drug use (20%). The median age at HIV
diagnosis was 35 years (range, 16-62). The majority of women (58%) within this group
lived in urban areas of the state. HIV was diagnosed first in 62 (75%) of the cHBV/HIV
co-infected cases and the median time to subsequent HBV diagnosis for these cases was 9
years (range, 2-21). In 22% of cHBV/HIV co-infected cases, both infections were
reported in the same year whereas only 4% of co-infected cases had an HBV diagnosis
reported first. Twenty-nine percent of the cHBV/HIV co-infected women in our study
had a concurrent diagnosis of HIV infection and AIDS within three months whereas 48%
were ever diagnosed with an AIDS infection. Triple infection with HBV, HCV and HIV
was present in a small number (n=7) of cases reported. A small proportion of aHBV cases
were also co-infected; 21(6%) cases also reported an infection with HCV whereas 9 (3%)
cases reported a co-infection with HIV.
Linkage between CHESS/eHARS and birth registry data
From the birth registry data, there were 226 894 women with available data on
infections presented or treated during pregnancy. Our final sample used for assessing
agreement between CHESS and birth registry included 344 HBsAg-positive women from
CHESS and 308 (0.13%) HBsAg-positive women identified from the live registry data
(Figure 2.3). After linkage, the estimated crude prevalence of HBV infection among
pregnant women within our sample was 0.17% (379/226,894). Only 159 (52%) HBsAg-

20

positive mothers were found reported to CHESS while the remaining 149 (48%) HBsAgpositive mothers from the birth registry data could not be found in CHESS. Conversely,
185 (54%) of HBV infected women from CHESS who had a singleton birth were not
identified as being HBsAg-positive mothers on their birth records even though they were
reported as being HBV infected prior to their pregnancy.
There was moderate agreement between CHESS and birth certificate data for
identifying HBsAg-positive women (Cohen’s k = 0.50 [95% CI= 0.47-0.54]). Percent
positive agreement was 49%.
Agreement of HIV cases from the birth data and eHARS could not be ascertained
because maternal HIV status is not recorded in the birth registry data. Four (6%) out of
the 68 HIV co-infected women who were of childbearing age had one singleton birth.
2.5 Discussion
This study used linked surveillance and birth registry data sources to describe the
epidemiology of HBV mono-infected and HBV/HIV co-infection among a populationbased sample of women. Overall, we found that approximately 9% of cHBV cases were
co-infected with either HIV (4.2%) or HCV (4.3 %). The majority of cHBV/HIV coinfected cases were Black women from urban areas in SC, who self-reported heterosexual
contact as the main risk factor for HIV transmission and had low first CD4 counts after
HIV was diagnosed. Women between the ages of 20 and 49 reported the highest
frequencies of disease occurrence in our study and this observation is consistent with
other empirical studies 74, 75 conducted in the US that have found that most HBV
infections occur in young adults with sexual contact being one of the most common
modes of infection 76. Within the state, the largest proportion of aHBV cases was reported
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from the northeastern region (Pee Dee), which could reflect poor vaccination coverage
for aHBV among women in this region.
In low endemic regions such as the US, cHBV/HIV co-infection occurs frequently
with estimated prevalences between 5% and 7% 19. In our study, we observed a moderate
prevalence of co-infection with HIV/AIDS and HCV among cHBV infected women
reported to CHESS; 4.2% were co-infected with HIV/AIDS, whereas 4.3% had a coinfection with HCV. The majority of co-infected women in our study had an HIV
diagnosis preceding an HBV diagnosis, suggesting that both infections were acquired in
adulthood and not through perinatal transmission. The 9-year median time between HIV
diagnosis and a subsequent chronic HBV diagnosis was a striking element in our study.
Routine HBV testing and immunization is recommended for all HIV-infected persons
and our finding suggests that there are gaps in compliance with this recommendation.
This implies that the HIV infected women who were also co-infected with cHBV lived
with undiagnosed viral hepatitis for long periods of time. Thus, opportunities to counsel
infected individuals and prevent further transmission were likely to have been missed.
Additionally, these results indicates a missed opportunity for those with undiagnosed
HBV to be put on appropriate medication that would treat both HIV and HBV as drug
resistance and fatal flares of HBV are both potential consequences resulting from
choosing the wrong therapy without knowledge of HBV status. Our results points to the
importance of routinely testing HIV infected persons for HBV infection and provide
HBV immunization for sero-negative individuals.
A large proportion of the HBV/HIV co-infected women in our study presented
with low CD4 counts and was diagnosed with AIDS almost immediately upon diagnosis.
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Although we cannot be certain of when these cases contracted HIV, the young median
age (35 years) and low CD4 counts at HIV diagnosis may suggest long duration of
infection. A recent study on missed opportunities for HIV testing among HIV infected
women from SC showed that 73% of cases had missed opportunity visits and among the
half that were late testers, about 79% were diagnosed with AIDS within a month of
receiving their HIV diagnosis 77. Because we were unable to assess missed opportunities
for HIV testing within our sample, we do not know what proportion of HBV/HIV coinfected women with AIDS also had missed opportunity visits for HIV testing.
In this study, among mothers who had one singleton birth, we found moderate
agreement between surveillance data and birth certificate data for maternal HBsAgpositive status. Among the prenatal population in SC, HBsAg infection comprised <1%
of all cases and the estimated prevalence of HBV infection among pregnant women
within our study was 0.17%. This was within the reported range of 0.09-0.27% 12, 28, 44, 48
for US women. Because screening for HBsAg sero-status is universally recommended
during pregnancy and at delivery for high risk women 71, we expect to find most, if not
all, positive HBsAg cases determined through prenatal screening in the states surveillance
system as reporting of HBV cases is required by law. When we assessed the degree of
concordance between CHESS and birth certificate data for mothers who had one
singleton birth, we discovered that for maternal HBsAg status, CHESS was in moderate
agreement with birth certificate data and only 52% of HBsAg-positive cases found on the
birth records were reported to CHESS. Surprisingly, even after excluding HBsAgpositive mothers who had births before an HBV diagnosis was reported to CHESS, 54%

23

of CHESS cases were designated as being HBsAg negative on their birth records and
52% of HBsAg-positive cases from the birth data were not reported to CHESS.
Several reasons may explain this observation. First, designated HBsAg-positive
cases per birth certificate could be false positives that were reported to CHESS and were
assigned a “suspected” or “not a case” status after a further case investigation.
Unfortunately the extent to which this is true could not be assessed in our data, as only
probable and confirmed cases were included in study sample. Secondly, we restricted our
data to only singleton births. HBsAg sero- positive mothers who had plural births and
reported to CHESS were not included in our analysis. Nevertheless, because 54% of
mothers who were confirmed as being HBsAg sero-positive were in CHESS but not
reported on their birth certificate for that singleton pregnancy raises concerns about the
quality of data collected for infections present during pregnancy on the birth certificate.
Historically, validation studies 78, 79 conducted on data from U.S. birth registry data have
shown it to be a reliable source of information. However, maternal HBV infection
present/and or treated during pregnancy was recently added as a data item on the revised
birth certificate and the validity and reliability of this measure has not been formally
evaluated. Additionally, the high number of HBsAg sero-positive cases not reported to
CHESS suggests infrequent passive reporting for HBV within the state and an
opportunity to strengthen ties with clinicians and other key partners engaged in disease
surveillance reporting.
The findings in this study are subject to at least three limitations. First, the
prevalence of HBsAg-positives in our study is very low thus, data agreement results
should be interpreted cautiously. Secondly, while HBV screening during pregnancy is
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universally recommended in US, it is likely that screening practices differ across
providers and this may have resulted in the misclassification of infected but unscreened
women in the birth certificate data. Furthermore, as the completeness of surveillance data
from CHESS is unknown, the data presented here is not representative of all the HBV
infected cases that occurred over the study period. Moreover, our data on HBV and HIV
diagnosis date reflects an approximate time for when these conditions were detected and
subsequently reported. We cannot determine when the either infections occurred or
confirm the order of infection for those women who were co-infected. Finally, CHESS
data did not capture several key demographic variables, most especially detailed race
information and HBV risk factor data, that could have strengthened our description of
this population.
In spite of these limitations there are strengths to our study. This study offers the
first description of HBV and HBV/HIV disease burden within the SC female population.
Moreover, this study employs a rich variety of data sources and uses a sequential record
linkage process that links reported cases of HBV to birth records. Lastly, being able to
assess how birth data for maternal HBsAg status compares to reported HBV surveillance
data identifies opportunities to enhance and strengthen disease reporting.
In summary, the prevalence of HBsAg infection among pregnant women was
within the reported range of previous estimates (0.09-0.27%). HIV and HCV co-infection
within this population was substantial and there was moderate agreement between
surveillance and birth registry data reported for maternal HBsAg status. HIV co-infected
women were largely young black adults who had their HBV diagnosed almost a decade
later and lived in urban areas. An increase in efforts to improve screening, reporting and
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prevention especially among black women is warranted. Our results also suggest that
reports of infections found during prenatal screening to the disease surveillance needs to
be improved. More training should be provided for birth record abstractors to promote
accurate reporting of this data to surveillance. Clinicians can educate mothers by
explaining the importance of data and its widespread use nationally to enhance reporting
accuracy. More importantly, using the birth registry data by itself to identify HBsAg
positive women may not be adequate and future studies can benefit from using both
surveillance data and birth data in identifying HBsAg-positive women.

26

Table 2.1- Demographics of hepatitis B virus (HBV) and HIV co-infected female cases in South
Carolina reported to CHESS and eHARS between 2004 and 2011

HBV-related variablesa
Number of cases
Age at HBV, years, median
(range)
≤20
20-29
30-39
40-49
50-59
≥60
Missing
Year of HBV diagnosis
2004
2005
2006
2007
2008
2009
2010
2011
Race
Black
White
Other
Missing
Hepatitis B vaccine received
indicator
No
Yes
Missing

Mono-infection
aHBV
cHBV
n (%)
n (%)
295
1754

Total
n (%)
2132
38 (1-91)
115 (5)
503 (24)
508 (24)
410 (19)

Co-infection
cHBV/HIV
n (%)
P-value
83

41 (1 - 85) 37 (1 - 91) 42 (21 - 63) <0.001b
3 (1)
112 (6)
<0.001c
46 (16)
450 (26)
7 (8)
86 (29)
83 (28)
43 (15)
30 (10)
4 (1)

311 (15)
267 (13)

395 (23)
301 (17)
248 (14)
234 (13)
14 (<1)

27 (33)
26 (31)
20 (24)
3 (4)
0
<0.001c

379 (18)
342 (16)
321 (15)
261 (12)
235 (11)
230 (11)
175 (8)
189 (9)

65 (22)
66 (22)
42 (14)
24 (8)

301 (17)
270 (15)
265 (15)
220 (13)

13 (16)
6 (7)
14 (17)
17 (20)

33 (11)
23 (8)

191 (11)
197 (11)

11 (13)
10 (12)

22 (7)
20 (7)

145 (8)
165 (9)

8 (10)
4 (5)

420 (20)
253 (12)
174 (8)
1285 (60)

81 (27)
58 (20)
11 (4)

274 (16)
180 (10)
160 (9)
1140 (65)

65 (78)
15 (18)
3 (4)

-

-

145 (49)

150 (51)

-

13 (4)
132 (45)
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0

<0.001c

Table 2.1- Demographics of hepatitis B virus (HBV) and HIV co-infected female cases in South
Carolina reported to CHESS and eHARS between 2004 and 2011 (cont’d.)

HBV-related variablesa
DHEC region
Low country
Midlands
Pee Dee
Upstate
Missing
Case classification
Confirmed
Probable

Mono-infection
aHBV
cHBV
n (%)
n (%)

Total
n (%)
501 (24)
594 (28)
400 (19)
435 (20)
202 (9)

61 (21)
75 (25)
90 (31)
38 (13)
31 (11)

1457 (68)
675 (32)

276 (94)
19 (6)

Co-infection
cHBV/HIV
n (%)
P-value
<0.001c
424 (24)
16 (19)
494 (28)
25 (30)
285 (16)
25 (30)
388 (22)
9 (11)
163 (9)
8 (10)

1135 (65)
619 (35)

46 (55)
37 (45)

<0.001c

HIV, human immunodeficiency virus; cHBV, chronic hepatitis B virus; aHBV, acute hepatitis B virus;
CHESS, Carolina’s health electronic surveillance system; DHEC, department of health and
environmental control.
*Percentages may not equal to 100 because of rounding.
a
HBV-related variables were obtained from CHESS surveillance database.
b
Kruskal Wallis p-value was calculated for continuous values.
c
Chi-square p-value was calculated for categorical values.
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Table 2.2 - Characteristics of chronic hepatitis B and HIV co-infected female cases in South
Carolina reported to CHESS and eHARS between 2004 and 2011
Co-infection
HIV-related variables

a

cHBV/HIV N (%)

Number of cases

83

Year of HIV diagnosis
1985-1989
1990-1994
1995-1999
2000-2004

3 (4)
15 (18)
23 (28)
16 (19)

2005-2009
≥ 2010
Age at HIV, years, median (range)
≤20
20-29
30-39

21 (25)
5 (6)
35 (16-62)
5 (6)
27 (33)
19 (23)

40-49
50-59

22 (27)
9 (11)
1 (1)

≥60
Timing of HIV-HBV diagnosis
HIV reported first
HIV and HBV reported togetherb
HBV reported first

62 (75)
18 (22)
3 (4)

HIV disease stage at diagnosis
HIV only
HIV and later AIDS

19 (23)
40 (48)

HIV and AIDS diagnosed simultaneously
HIV transmission category
Injecting drug use

24 (29)
17 (20)

Heterosexual
No identified riskc
Otherd

47 (57)
18 (22)
1 (1)
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Table 2.2- Characteristics of chronic hepatitis B and HIV co-infected female cases in South
Carolina reported to CHESS and eHARS between 2004 and 2011(cont’d.)
Co-infection
HIV-related variables

a

cHBV/HIV N (%)

Source of HIV report
County health department

18 (22)

Hospital
Group practice
Other statee
Otherf

19 (23)
12 (14)
11 (13)
5 (6)

Unknown
Residence at time of HIV diagnosis
Urban
Rural
Missing
CD4+ percentage

18 (22)

No. of women with data available
0-25%

81
57 (70)

26-40%
≥40%
First viral load group
No. of women with data available
≤ 10,000 copies/mL

21 (26)
3 (4)

> 10,000 copies/mL
First CD4+ count
No. of women with data available

51 (67)

48 (58)
19 (23)
16 (19)

76
25 (33)

81

2

Median (IQR) cells/mm
First viral load
No. of women with data available

189 (58-494)
76

Median (IQR) copies/mL

28561 (4762-114635)

HIV, human immunodeficiency virus; cHBV, chronic hepatitis B virus; IDU, injecting drug use; mL,
milliliter; CD4, cluster of differentiation 4;
*Percentages may not equal to 100 because of rounding.
a
These variables were obtained from the enhanced HIV/AIDs reporting system (eHARS).
b
HIV and HBV were diagnosed and reported in the same year.
c
Adults with no risk factors reported (n=4) or no identified risk factors (n=14).
d
Other risk category includes heterosexual who had sexual intercourse with a high-risk individual (e.g.,
IDU, male bisexual, transfused individual, HIV-positive individual)
e
Other state includes reports from other states.
f
Includes blood banks/business (n=1); private physician (n=1); state (n=2); department of mental health
(n=1);
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Figure 2.1 Data sources and linkage process
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Figure 2.2 Sample population and flow for hepatitis B virus (HBV) female cases from CHESS linked with HIV data
from eHARS; January 1, 2004 to December 31, 2011.

CHESS/eHARS

Data linkage

1 556 HBsAg-positive women

Birth Registry Data
226 894 women with one pregnancy

379 had one singleton birth
Excluded 35 women that
had births occur before
HBV diagnosis
308 HBsAg-positive women
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344 HBsAg-positive
with a live birth

185a HBsAg-negative on
birth certificate
a

159 reported to
CHESS

149 not reported to
CHESS

9 were acute HBV reports and 177 were chronic cases

Figure 2.3 Sample population for hepatitis B virus (HBV) female cases from CHESS/eHARS linked with birth registry;
January 1, 2004 to December 31, 2011.

CHAPTER 3
HEPATITIS C VIRUS (HCV), HCV/HEPATITIS B VIRUS (HBV) AND HCV/HIV
CO-INFECTION AMONG REPORTED FEMALE CASES IN SOUTH CAROLINA

3.1 Abstract
Few data exist on the magnitude of Hepatitis C virus (HCV) mono-infection, and its coinfection with hepatitis B virus (HCV/HBV) and human immunodeficiency virus
(HCV/HIV) within the US female population. This study describes the burden of HCV,
HCV/HBV and HCV/HIV co-infection, demographic characteristics and the order of
HCV/HIV virus diagnosis in women in South Carolina (SC). The study used a linked
dataset of surveillance data that was reported from HCV-, HBV- and HIV-infected
female cases that occurred in SC between 2004 and 2011. We identified a total of 10,208
HCV-positive reports. Ninety-five percent were mono-infected with HCV, followed by
4% who were co-infected with HCV/HIV and 1% with HCV/HBV infection. HCV
mono-infected cases overall were predominantly middle-aged White women. However,
after stratifying our results by age for those with available race information (40%), we
observed an increase over the study period in the number of HCV infections reported for
White adolescents and young adults aged 15-25 years old. HCV/HIV co-infected cases
tended to be Black middle-aged women from urban areas who reported either intravenous
drug use (IDU) or heterosexual contact as their main risk factor for HIV transmission.
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HIV was diagnosed first in 79% of HCV/HIV co-infected cases and 62% of HCV/HBV
co-infected cases had both infections reported within the same year. Our findings suggest
a need for resources to be directed at improving screening and prevention efforts among
middle-aged White women, Black women and young persons between the ages of 15 and
25 years.
3.2 Introduction
Hepatitis C virus (HCV) infection is the most common chronic blood-borne
infection in the United States (US) and remains a global leading cause of liver-related
morbidity and mortality 80, 81. The estimated number of HCV-infected individuals
worldwide is staggering. Between 130-170 million, 2-3% of the world’s population, are
chronically infected with HCV 82. In the US, taking into account institutionalized,
incarcerated and homeless persons, there are at least 3.5 million individuals who are
infected with chronic HCV 83, 84. In one recent study, when active military service
personnel, nursing home residents and immigrants were accounted for, as many as 5.2
million individuals in the US were reported to be living with chronic HCV infection 13.
Among individuals infected with human immunodeficiency virus (HIV), coinfection with HCV is very common as these two infections share common risk factors
for transmission. Of the estimated 1.3 million HIV-infected Americans, about 25% are
co-infected with HCV and among HIV patients who have a history of either intravenous
drug use (IDU) or hemophilia, HCV/HIV co-infection rates ranges from 70 to 95% 20, 21
19

. For individuals living with both viruses, HIV adversely affects the natural history of

HCV disease 85, 86. Thus, co-infection is associated with severe disease, high HCV viral
loads, a faster progression to liver disease and an increased rate of decompensated liver-
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related mortality3, 23, 24, 85 87, 88. These adverse clinical outcomes are also seen among
those co-infected with both HCV and hepatitis B virus (HBV). Compared to a single
hepatitis infection, co-infection with HCV and HBV is associated with a higher
prevalence of liver cirrhosis, liver decompensation as well as an increased risk of
developing liver cancer 89-91.
In order to evaluate the burden and trends of HCV adequately, HCV prevalence
should be stratified by age, ethnicity and gender 82. However, unanswered questions exist
concerning the epidemiology of HCV, HCV/HIV and HCV/HBV infection within the
female population. Specifically, for women in their childbearing years and those who are
pregnant, the prevalence of HCV has not been well-studied 28. Estimates from the
National Health and Nutrition Examination Survey (NHANES) estimates HCV
prevalence in US women at close to 1% 27, 84, whereas estimates using US birth data have
yielded prevalence rates that fall between 0.06 and 0.2% 28, 44, 50. Yet, these data do not
take into account certain populations, such as homeless or incarcerated persons, that are
at high risk for HCV infection 13. Additionally, the completeness of reporting HCV
infection on the US birth certificate is unknown and because universal screening of HCV
during pregnancy is not mandatory, ascertainment bias could likely influence these HCV
prevalence estimates from birth certificates 50.
Surveillance data offer an alternative opportunity to overcome some of these
limitations through the use of a population-based sample. Beyond being a valuable
epidemiologic tool for descriptive analysis, surveillance data avoids some biases found in
population surveys in that data are reported from all sources, including hard to reach
populations 92. To the best of our knowledge, there are no studies that have used
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surveillance data to characterize the burden of HCV, HCV/HIV and HBV-HCV infection
within a female population.
In this study, we used data collected through South Carolina’s (SC) viral hepatitis
and HIV/AIDS surveillance system to report on the prevalence, demographic
characteristics, patterns of CD4+ T-lymphocyte count (CD4), sequence of virus diagnosis
and risk factors at time of HIV infection among HCV-positive females in SC. In our
previous study 93, we described characteristics associated with HBV and HBV/HIV coinfection and assessed the extent of agreement between the electronic birth registry and
disease surveillance data.
3.3 Methods
Data sources
Two data sources were obtained from the SC Department of Health and
Environmental Control (DHEC) and used for this study: the South Carolina (SC) Health
Electronic Surveillance System (CHESS) and the enhanced HIV/AIDS Reporting System
(eHARS). The CHESS database containing all the HCV and HBV (probable or
laboratory-confirmed) cases was linked to eHARS database that contains HIV case
reports. Approval was received from SC DHEC and the University of SC Office of
Research Compliance.
CHESS data
In SC, all positive laboratory results (confirmed and probable) indicating HCV
infection are required by law to be reported to SC DHEC and are recorded in CHESS 69.
This web-based infrastructure is a passive surveillance system and is part of the Centers
for Disease Control and Prevention (CDC) National Electronic Disease Surveillance
37

System (NEDSS) which has been used for disease surveillance and reporting since 2004
94

. A trained DHEC specialist reviews all positive HCV tests recorded in CHESS to

ensure that each notified case meets the case definition for HCV as set forth by the CDC
guidelines. In accordance with these surveillance guidelines, a confirmed chronic HCV
case (past or current infection) was defined as a positive anti-HCV assay with either a
positive nucleic acid test (NAT) result or a positive recombinant immunoblot assay
(RIBA) test to further confirm HCV infection. Conversely, all positive anti-HCV assay
reports where neither a NAT nor RIBA test was conducted or reported to SC DHEC and
did not meet the case definition for an acute HCV case were defined as probable chronic
HCV cases. Because no laboratory distinction can be made between a previous or
current infection and includes about 20% of persons who resolved their infections,
confirmed chronic HCV cases represent “past or present” HCV infection 95.
For our analysis, all confirmed or probable female cases with a report date
between January 1st 2004 and December 31st 2011 were extracted from CHESS along
with demographic data on the reported age, race and zip code. To identify HCV/HBV coinfected cases, the same inclusion criteria were applied to extract HBV infected cases
from CHESS. This data were described elsewhere 93.
Enhanced HIV/AIDS Reporting System (eHARS)
HIV is a mandatory reportable disease in SC and since 1986, all newly identified
cases of HIV infection who are residents of SC has been reported to the eHARS.
Recorded in the eHARS database are demographic variables, CD4 counts and HIV viral
loads. Based on a routine assessment of the database for accuracy and completeness, the
quality of data from eHARS exceeds the CDC minimum standards on reporting
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timeliness and completeness; 95% within six months of a diagnosis and 98%
completeness based on comparison with other data sources [SC DHEC, unpublished data,
2010]. For our analysis, female cases of HIV/AIDS who were reported to eHARS by
December 2011 were eligible to be selected for potential linkage to CHESS cases.

Data linkage
A trained statistician from DHEC performed the data linkage for this study. Using
probabilistic matching methods, HCV-positive cases from CHESS were linked to HIV
positive records from eHARS. Each record was matched on gender, name, race, social
security number and date of birth. After linkage the final dataset contained no identifiers.
Statistical analysis
We compared demographic differences for HCV- and HIV-related variables
across groups of women identified with HCV mono-infection, HCV/HIV or HCV/HBV
co-infection over the 8-year study period. Frequencies and percentages for each level of
categorical variables were calculated and the Chi-square (χ2) statistic was used for
comparison. Continuous data such as age and CD4 counts were expressed as median and
range or median and interquartile range (IQR) as appropriate.
We determined the sequence of virus diagnosis for both HCV/HIV and
HCV/HBV co-infected cases by obtaining the difference in time between the year either
HIV or HBV was reported and the year HCV was reported. The prevalence of HBV
infection among those infected with HCV was calculated as the proportion of HCV cases
with a positive hepatitis B surface antigen report (HBsAg) in CHESS during the study
period. HBsAg positive cases from CHESS included probable or confirmed cases that
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were either acute or chronic HBV infections. All data were analyzed using SAS (version
9.3, SAS Institute Inc.) and R statistical program 96.
3.4 Results
A total of 10,208 reports from female cases of HCV were received in CHESS
over the 8-year study period (Figure 3.1). Of these reports, 11 (<1%) were acute HCV
cases and the remaining 10,197 were chronic HCV cases. Our analysis was limited to the
portion of the sample that had a chronic HCV infection (Table 3.1 and 3.2).
HCV mono-infection
Of the total 10,197 chronic HCV cases reported, 9,664 (97%) were mono-infected
and of these, 8,469 (88%) cases met the clinical definition for a confirmed case. The
median age at HCV notification was 48 years (range 1-79 years). Forty percent (3,856) of
mono-infected cases had available race information. Among these, 27% were White and
12% were Black. An average of 1,208 prevalent cases were reported each year with the
western (Upstate) and central (Midlands) regions of the state reporting the largest
proportions (26% and 21%) of monoinfected cases respectively.
When the age distribution for the number of monoinfected cases were stratified by
race (for those with available race information) and compared for years 2004 and 2011,
we noted a difference by race (Figure 3.2). For White females, the mean age decreased
from 45 years in 2004 to 44 years in 2011 while the variance increased from 139.6 in
2004 to 195.7 in 2011. For Black females, the mean age increased from 50 years in 2004
to 55 years in 2011 whereas the variance increased slightly from 131.6 in 2004 to 139 in
2011.
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HCV/HIV co-infection
HCV/HIV co-infection prevalence in this sample was 4% (95% CI: 3.9% - 4.7%)
and the median age at the time of HCV diagnosis was 48 years (range, 18-75 years). The
majority of co-infected cases were Black (76%) whereas 21% were White. Almost half of
HCV/HIV co-infected cases (46%) reported IDU as the main risk factor for HIV
transmission and this was followed by 38% of cases that reported heterosexual exposure
as a risk factor. The majority of cases (59%) resided in urban areas whereas over 50% of
the HIV reports were from hospitals and county health departments. HIV was diagnosed
first in 340 (79%) cases and among these cases, the median time to subsequent HCV
diagnosis was 9 years (range, 1-23 years). Although 16% had both infections reported in
the same year, 5% of HCV/HIV cases had an HCV diagnosis reported first. AIDS disease
stage was diagnosed in 42% of HCV/HIV cases whereas only 34% were HCV/HIV cases
without AIDS. At the time of HIV presentation, the median age was 40 years (range, 1669 years), and the median CD4 cell count and viral load were 307 cells/µL (IQR 156-528
cells/µL) and 14,000 copies/mL (IQR 1,780-73,860 copies/mL), respectively.
HCV/HBV co-infection
There were 101 (7%) cases of HCV that were co-infected with HBV. Seven of
these cases, also had an infection with HIV, i.e., these individuals had a triple infection
with HCV, HIV and HBV. Of the 94 cases that remained, 20 (21%) were an acute HBV
infection while 74 (79%) had a chronic infection with HBV. At the time HCV was
reported, the median age was 49 years (range, 21-79) and 84% met the clinical definition
for a confirmed HCV case. When we considered the 40 (43%) cases with available race
information, notifications from White women made up the largest proportion (26%).
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HCV and HBV infections were reported within a year of each other in majority (62%) of
the cases and only 16% had their HBV infection reported first.
3.5 Discussion
Our data showed that for the 40% of HCV mono-infected cases with available
race information, middle-aged White women were predominant and who were most
likely to reside in the western (Upstate) and central (Midlands) regions of the state. These
findings are consistent with what is already known about HCV infection from national
data. The NHANES data from 1999-2002 showed that anti-HCV prevalence was highest
among individuals between the ages of 40 and 49 years 84. Additionally, a recent
NHANES study using data from 2001-2010 revealed that more than two-thirds (70.1%)
of US sero-prevalent HCV cases belonged to 1945-1965 birth cohort 97. In our study,
65% HCV mono-infected cases were in the 40-59 years age group that corresponds to
1952-1970 birth cohort. Within this cohort, persons born between 1945 and 1964 were
between the ages of 40 and 59 in 2004. From the NHANES data, even though the
national prevalence of females infected with HCV is estimated to be around 1.1%84, this
data covers only non-institutionalized persons meaning that active military personnel,
incarcerated, homeless, hospitalized individuals are excluded from this estimate 13.
Furthermore, epidemiologic data on HCV mono-infection and HCV/HBV or HCV/HIV
co-infection in female populations are rare. Because women constitute a large proportion
of the total adult population, monitoring HCV prevalence trends, as has been previously
done with the HIV epidemic, is useful for assessing the extent of HCV infection within
the general population. To the best of our knowledge, this study represents one of the
largest cohorts of HCV-positive women whose co-infection status was identified using
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surveillance data.
Our findings add to previous evidence about HCV infection to reveal that there
has been a substantial increase from 2004 to 2011 in the number of HCV infections in
adolescents and young adults between the ages of 15 and 25 years. When we compared
the age distribution for cases reported in 2004 and those reported in 2011, we observed an
increase in the variance for 2004 and 2011. Similar observations were also reported from
three studies 1, 98, 99 that used HCV surveillance data from Massachusetts, New York and
Wisconsin. In these studies, the young adults were predominantly White residents in rural
and urban communities and IDU was associated with the observed increase 1, 98, 99. In our
study, when we looked at age distribution by race for cases with available race
information, the results for White women appeared to be evident than those for Black
women. It should be noted that since race information was missing for over 57% of
reported HCV cases, caution should be applied to the interpretation of these results.
Furthermore, since we lacked data on HCV risk history for these cases reported, we were
unable to assess if IDU explained the observed increase in the number of HCV cases
reported for young adult and adolescents in 2011.
HCV/HIV co-infection was present in 4% of all the chronic HCV cases. These
were primarily Black middle-aged women from urban communities in SC who had their
HIV infection identified first, reported IDU as the main risk factor for HIV transmission
and had a median CD4 count of 307 cells/mm2 (IQR 156-528 cells/mm2) at baseline
testing. Our results are comparable to findings from a US study that used HIV-infected
women visiting a prenatal clinic and reported an HCV/HIV prevalence of 4.9% 34.
Conversely, other US epidemiological studies on HCV/HIV co-infection have yielded
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prevalences between 16% and 36% 100-102, although these studies were conducted
primarily in HIV-positive cohorts that were disproportionately male. We obtained the
number of women reported to be living with HIV/AIDS in SC as of December 2011 to
determine the proportion of HIV infected women that are co-infected with HCV. We
estimated that 9.4% (432/4,578) of HIV positive women are co-infected with HCV/HIV.
Because of shared routes of transmission for both HCV and HIV infections, it is
not surprising that in our study, IDU and heterosexual contact were the most common
self-reported HIV risk factor. HIV was diagnosed first in 79% of the cases and the 9-year
median time between HIV and a subsequent chronic HCV diagnosis is a significant
finding. CDC and the US Preventive Services Task Force recommend HCV screening in
HIV infected individuals at the time of entry into health care but does not recommend a
frequency after baseline screening. Our finding here could help make the case for
recommending routine HCV screening amongst HIV-positive individuals, especially
those known to be injection drug users. Early detection of HCV infected individuals can
prevent further transmission, help select the appropriate medication for treatment and
consequently reduce HCV-related mortality within this population.
One explanation for why HCV was reported much later in the majority of our
HCV/HIV co-infected cases is that HIV increases susceptibility of infected women to
sexually acquired HCV 103, thus, it is likely the HCV infection was acquired as a
consequence of being infected with HIV. In one cross-sectional study among HIVpositive women reporting no history of IDU, heterosexual contact with a male drug
injector was associated with being HCV positive 104. Conversely, in a Canadian study that
used surveillance data from both genders, the authors reported HCV diagnosed first in
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52% of their cases and this was independently associated with IDU behavior 105.
Although we were unable to assess the extent to which IDU or heterosexual contact was a
risk factor for HCV transmission in this study, it is likely that both heterosexual contact
and IDU were risk factors in HCV acquisition.
Lastly, 1% of our cases were co-infected with HCV/HBV and this estimate was
comparable to an estimate of 1.4% recently reported by Tyson et al. 106. In other US
studies 27, 107, 108 higher prevalences for past HBV exposure among HCV cohorts have
been reported to range from 25%-65%. Our HCV/HBV co-infected women had their
HBV diagnosed first and this is likely due to universal screening practices for HBV
infection during obstetric care. In contrast to Bini et al. 107 who reported HCV/HBV coinfection to be highest amongst individuals with age less than 40 years, we found that
67% of our HCV/HBV cases were between the ages of 40 and 59 years old.
Our findings here are limited because the completeness of HCV surveillance data
from CHESS is unknown. Also, our HCV data is biased towards persons more likely to
have health insurance and to be receiving health care. Thus, this data may not be a
representative sample of all the HCV-infected cases that occurred over the study period.
We could not estimate the prevalence of HCV infection in our study due to the lack of a
true denominator for our surveillance cases. Furthermore, our data on diagnosis date for
HCV, HBV and HIV infection reflects approximate times for when these conditions were
detected and subsequently reported. However, we cannot determine when these infections
occurred or confirm the order of either HCV/HIV or HCV/HBV infection for those who
were co-infected. Finally, several missing data from key demographic variables, such as
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race/ethnicity and HCV risk factor, in the CHESS database may have weakened our
description of this population.
Our study offers the first description of HCV/HIV and HCV/HBV co-infection
prevalence within the SC female population. The use of statewide surveillance data to
ascertain the co-infection status of HCV-infected female cases is another strength of this
study. Finally, our study represents one of the largest cohorts of HCV-infected females in
the US. Characteristics of these HCV mono-infected and co-infected women can be used
to target screening and prevention efforts at the local and state level.
In summary, our results appear to be consistent with what is already known about
HCV infection. HCV mono-infected cases were predominantly middle-aged White
women whereas those co-infected with HCV/HIV were largely Black middle-aged
women from urban areas who reported either IDU or heterosexual contact as their main
risk factor for HIV transmission. There was a substantial increase in the number of HCV
infections reported for adolescents and young adults between the ages of 15 and 25 years.
Our co-infection prevalence was close to the reported range of previous estimates of
4.9%- 36% and 1.4%-65% for HCV/HIV and HCV/HBV respectively.
The findings suggest a need for resources to be directed at improving screening
and prevention efforts among Black and White middle aged women and most especially,
in young persons between the ages of 15 and 25 years. Over three-thirds of the HCV/HIV
infected women in our study belonged to the 1945 to 1965 birth cohort. These individuals
benefit from combined testing for HIV and HCV infections. Not only will this approach
be cost-effective, it can lead to the timely identification of HCV/HIV co-infected
individuals. HIV-infected individuals with IDU as a risk factor or heterosexual contact
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with male IDU should be routinely screened for HCV because of the risk of ongoing
exposure to HCV. Because HCV risk behavior and detailed race information were
unavailable for analysis in our HCV surveillance data, initiatives to fund and improve
HCV case reporting data are warranted.
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Table 3.1- Demographics of hepatitis C (HCV), hepatitis B virus (HBV/HCV) and HIV coinfected female cases in South Carolina reported to CHESS and eHARS between 2004 and 2011
Co-infection
HCV-related variables

a

Number of cases

HCV/HBV
n (%)

HCV/HIV
n (%)

HCV
n (%)

94

432

9664

Age at HCV, years, median (range) 49 (21 - 79) 48 (18 - 75)
≤20
0
1 (<1)
20-29
30-39
40-49
50-59
≥60
Missing
Year HCV was reported
2004
2005
2006
2007
2008
2009
2010
2011
Race
Black
White
Other
Missing
Case classification
Confirmed
Probable
DHEC region
Low country
Midlands
Pee Dee
Upstate
Missing

Mono-infection

48 (1 - 99)
136 (1)

5 (5)

15 (3)

755 (8)

13 (14)
33 (35)
30 (32)
12 (13)
1 (1)

57 (13)
190 (44)
145 (34)
22 (5)
2 (<1)

1229 (13)
3157 (33)
3113 (32)
1219 (13)
55 (<1)

P-valuec

<0.001

0.018
13 (14)
20 (21)
13 (14)
14 (15)
9 (10)
12 (13)
8 (8)
5 (5)

54 (13)
60 (14)
65 (15)
62 (14)
70 (16)
50 (12)
47 (11)
24 (6)

1014 (10)
1385 (14)
1447 (15)
1299 (13)
1293 (13)
1048 (11)
1054 (11)
1124 (12)

13 (14)
24 (26)
3 (3)
54 (57)

330 (76)
92 (21)
7 (2)
3 (1)

1184 (12)
2562 (27)
110 (1)
5808 (60)

<0.001

79 (84)
15 (16)

381 (88)
51 (12)

8469 (88)
1195 (12)

0.53

21 (22)
30 (32)
13 (14)
15 (16)
15 (16)

91 (21)
134 (31)
82 (19)
59 (14)
66 (15)

1752 (18)
2073 (21)
1706 (18)
2530 (26)
1603 (17)

<0.001
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Table 3.1- Demographics of hepatitis C (HCV), hepatitis B virus (HBV/HCV) and HIV coinfected female cases in South Carolina reported to CHESS and eHARS between 2004 and 2011
(cont’d.)

HCV-related variables

a

Timing of HCV/HBV diagnosis
HBV reported first
HCV and HBV reported concurrentlyb
HCV reported first

Co-infection

Mono-infection

HCV/HBV HCV/HIV
n (%)
n (%)

HCV
n (%)

P-valuec

16 (16)
63 (62)
22 (22)

HIV, human immunodeficiency virus; HBV, hepatitis B virus; HCV, hepatitis C virus; CHESS, Carolina’s
Health Electronic Surveillance System; DHEC, Department of Health and Environmental Control
*Percentages may not equal to 100 because of rounding.
a
HBV-related variables were obtained from CHESS surveillance database.
b
HBV and HCV were reported to CHESS within the same year of diagnosis.
c
Pearson Chi-square value
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Table 3.2- Characteristics of hepatitis C and HIV co-infected female cases in South Carolina
reported to CHESS and eHARS between 2004 and 2011
Co-infection
a

cHCV/HIV (N %)

Total number of cases

432

HIV-related variables

Year of HIV diagnosis
1985-1989
1990-1994
1995-1999
2000-2004

26 (6)
81 (19)
96 (22)
108 (25)

2005-2009
≥ 2010
Age at HIV, years, median (range)
≤20
20-29
30-39

92 (21)
29 (7)
40 (16-69)
11 (3)
56 (13)
144 (33)

40-49
50-59

154 (36)
56 (13)
9 (2)

≥60
Timing of HIV-HCV diagnosis
HIV reported first
HIV and HCV reported togetherb
HCV reported first

340 (79)
67 (16)
25 (5)

HIV disease stage at diagnosis
HIV only
HIV and later AIDS

149 (34)
181 (42)

HIV and AIDS diagnosed
simultaneously
HIV transmission category
Injecting drug use
Heterosexual
No identified riskc
Otherd
Residence at time of HIV diagnosis
Urban
Rural

102 (24)

197 (46)
166 (38)
68 (16)
1 (<1)
254 (59)
102 (24)
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Table 3.2. Characteristics of hepatitis C and HIV co-infected female cases in South Carolina
reported to CHESS and eHARS between 2004 and 2011 (cont’d.)
Co-infection
HIV-related variables

cHBV/HIV (N%)

Source of HIV report
County health department

97 (22)

Hospital
Group practice
Other statee
Otherf
Unknown
CD4+ percentage

125 (29)
49 (11)
54 (13)
28 (6)
79 (18)

No. of women with data available
0-25%
26-40%
≥40%
First viral load group
No. of women with data available
≤ 10,000 copies/mL

424
258 (60)
124 (29)
42 (10)

>10,000 copies/mL
First CD4+ count
No. of women with data available
median (IQR) cells/µL
First viral load
No. of women with data available
median (IQR) copies/mL

207 (48)

381
174 (40)

427
307 (156-528)
381
14000 (1780-73860)

HIV, human immunodeficiency virus; HCV, hepatitis C virus; HBV, hepatitis B virus; CD4, cluster of
differentiation 4; mL, milliliter; IDU, injecting drug use.
*Percentages may not equal to 100 because of rounding.
a
These variables were obtained from the enhanced HIV/AIDS Reporting System (eHARS).
b
HIV and HCV were diagnosed and reported in the same year.
c
Adults with no risk factors reported (n=17) or no identified risk factors (n=51).
d
Other risk category includes heterosexual who had sexual intercourse with a high-risk individual (e.g.,
IDU, male bisexual, transfused individual, HIV-positive individual)
e
Other state includes reports from other states.
f
Includes blood banks/business (n=5); private physician (n=5); state (n=17); department of mental health
(n=1)
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Figure 3.1
.1 Sample population and flow for hhepatitis
epatitis C virus (HCV) female cases reported to CHESS linked with
HIV data from eHARS; January 1, 2004 to December 31, 2011
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CHAPTER 4
SPATIAL ANALYSIS OF HEPATITIS C VIRUS AMONG REPORTED FEMALE CASES
IN SOUTH CAROLINA: AN ECOLOGICAL STUDY

4.1 Abstract
Chronic Hepatitis C virus (HCV) is a continuing global public health threat
affecting millions worldwide and in 2007 the number of HCV-related deaths exceeded
the number of HIV-related deaths in the United States. The purpose of this study was to
investigate the spatial distribution of reported female cases of HCV in South Carolina
(SC) so as to identify areas with high risk for HCV infection and describe their
characteristics for targeted public health action. Additionally, we assessed if the number
of drug abuse treatment admissions, an indicator for drug use, was a potential explanatory
covariate for HCV risk in these areas. We evaluated aggregated counts of reported HCVinfected female cases that occurred in SC between 2004 and 2011. Using a Bayesian
hierarchical spatial model that included potential confounders, a map with smoothed
standardized morbidity ratio’s (SMR) for HCV disease was created for each of the 46
counties in SC. Of the 10, 197 HCV-infected reports received for the study period, 8,511
(83.5%) reports with geographical information were used for our spatial analysis. There
was significant variation in the HCV risk among the counties in SC. Nine out of the
fourteen counties with a smoothed SMR >1 were statistically significant. These high-risk
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counties were mainly located along the coastal, midland and mountain regions of the
state. Even though six of these high-risk counties were areas with metropolitan centers,
the remaining three were federally designated rural counties that had low per capita
incomes and a large proportion of its residents living in poverty. We found no link
between the number of drug abuse treatment admissions and HCV risk among these
counties. Our results establish that there are areas in SC where the observed count for
HCV infections is higher than expected. Targeted public health action is needed to help
reduce the risk of the disease in these areas, especially in those rural counties. Future
research should consider other unmeasured factors so as to better understand the
underlying cause for high HCV risk in these counties.

4.2 Introduction
Chronic Hepatitis C virus (HCV) is the most common blood-borne infection and
the leading indication for liver transplantation in the United States (US) 109, 110. There are
at least 3.5 million US residents who are infected with HCV 83, 84. Of the three types of
viral hepatitis (hepatitis A, B, and C), HCV accounted for the most deaths and had the
highest death rate between years 2006 and 2010 61, 111. As of 2007, the number of HCVrelated deaths in the US exceeded the number of HIV-related deaths 5.
HCV is largely transmitted through percutaneous exposure to infected blood and
injecting drug use (IDU) is often the principal risk factor for disease transmission. Thus, a
substantial proportion of ‘newly diagnosed’ HCV infections are confined to individuals
who have a history of injecting drugs or are current injecting drug users (IDUs) 97.
National trends reveal an emerging epidemic of HCV infections among young non-urban
IDU’s across the country 1, 98, 112. In South Carolina (SC), surveillance data from a
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descriptive study that used reported HCV-infected female cases uncovered a similar
pattern; there was a substantial increase in the number of HCV infections reported for
white females between the ages of 15 and 25 years after comparing 2004 data to 2011
data 113. In spite of these findings the spatial epidemiology of these HCV-infected cases
have not been investigated and it is unknown if these reported HCV cases occur more in
rural SC as has been previously reported in other US states 1, 98, 99.
Disease mapping provides a visual representation of how disease is
geographically dispersed. Assessing the geographic distribution of disease cases,
especially those recorded through disease surveillance, has the potential of identifying
areas of unusual high risk so that public health action may be taken 114. Such initial work
can enable better resource allocation and efficient risk assessment as well as enhance
policy decision-making 114. Furthermore, disease mapping may generate new causal
hypothesis that can be used to provide context for future analytical studies 115.
Increasingly in spatial epidemiology, Bayesian small area risk models have been
consistently used to map disease risks as well assess associations between potential
explanatory covariates and disease risk estimates. Yet, there is only one US study 116 to
date that has employed the use of these Bayesian disease mapping techniques to evaluate
the geographic distribution of HCV cases reported through disease surveillance.
Using previously reported data 113, we conducted an ecological spatial analysis of
prevalent HCV females cases in SC from 2004 to 2011 to identify which counties in SC
exhibit elevated risks for HCV infection and to describe the population characteristics of
these identified high-risk areas. Additionally, we assessed the total number of drug abuse
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treatment admissions within these counties as a potential explanatory covariate for HCV
disease risk.

4.3 Methods
Hepatitis C data
The SC Division of Acute Disease Epidemiology (DADE) provided the viral
hepatitis data for this analysis. We included all confirmed or probable female cases of
HCV with a report date between January 1st, 2004 and December 31st, 2011 along with
demographic data on the reported age, race, zip code and county of residence. The case
definitions used here and database from which these cases were extracted from have been
described elsewhere 113. Approval was received from SC Department of Health and
Environmental Control (SCDHEC) and the University of SC Office of Research
Compliance.
Drug abuse treatment admission data
Drug abuse treatment admission is an indicator of illicit drug use several studies
used it to monitor national trends in drug use and abuse have 117-119. Aggregated county
data on the number of admissions for drug abuse treatment came from the Department of
Alcohol and other Drug Abuse Services (DOADAS). Publicly funded drug abuse
treatment facilities in SC are required to report patient information recorded at the time of
intake to DOADAS. Reported data elements include the patient’s primary or secondary
substances of abuse, the route of intake, age, gender, race, county of residence, type of
treatment and prior treatment admissions. DAODAS data covers all admissions rather
than individuals, therefore, one individual may be represented multiple times in the
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dataset. For the purpose of our analysis, we only considered unique admissions for where
the primary, secondary or tertiary substance of abuse involves cocaine,
methamphetamine, opiates, sedatives or stimulant use. Only treatment admissions for SC
female residents that occurred from 2005 to 2011 were used for our analysis. Data from
2004 was unavailable and therefore not included in our analysis. We excluded any
treatment admissions for patients whose primary or secondary substance abuse problem
was listed as alcohol, marijuana or hashish.
Geographic location and population data
Our geographical unit of analysis was the county and we considered all 46
counties within the state for our spatial analysis. Data describing the population and
socio-economic conditions within each county were obtained from the US Census
Bureau, USA counties data file download 120 and included as potential confounders of
HCV disease risk in our Bayesian hierarchical model. After review of literature, our list
of potential confounders included the proportion of White female residents (race) in
2007, proportion of persons aged ≥ 24 with a bachelor’s degree or higher (education)
between 2005 and 2009, percentage of foreign born residents from 2005-2009, as an
indicator of resident immigrant population and percentage of people of all ages living in
poverty in 2007. Population counts of females residing in each county were total average
female population count from 2004 to 2011, and this was also obtained from US Census
Bureau. These data were used to calculate indirectly standardized morbidity ratios (SMR)
described below. The geographic boundary file used in this was study was downloaded
from the SCDHEC geographic information systems data-clearing house.
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Spatial analysis
This study is ecological and investigates the spatial distribution of HCV infection
within the state of SC. We performed our spatial analysis of reported HCV-infected cases
in three steps: First, we estimated the expected number of HCV cases in each county.
Expected counts are based on the size of the population living in each county. Secondly,
we calculated the standardized morbidity ratio (SMR) for HCV cases in each county, by
dividing the observed counts of HCV-infected cases by the expected number. SMR
values above one represent areas with elevated levels of disease risk whereas values
below one indicate an area of reduced disease risk. Lastly, using a full Bayesian
approach, a geographically weighted Poisson model with a random spatial effect term
was applied to ‘smoothen’ the raw SMRs before mapping 121. This last step was repeated
for an unadjusted model, a model that only included our main covariate of interest and a
final model that included all the potential confounders and our main covariate of interest.
Bayesian spatial smoothing of SMRs for small area disease mapping reduces
random fluctuation of rates from unstable SMRs due to small counts and small
population sizes 114, 122-124. Since HCV counts are often small and rare, case counts were
modeled with a Poisson distribution. We used a Bayesian hierarchical model with a loglink, proposed by Besag, York and Molli

(BYM model) in 1991 125, to fit the raw

SMR’s with our covariate of interest (total number of drug treatments) and potential
confounders. The BYM model is a hierarchical model that uses a conditional autoregressive distribution and incorporates the effect of neighboring areas under study 126 124,
125

. Put differently, the BYM model shrinks unstable risks toward the local mean risk by

“borrowing” information between neighboring areas 127. We standardized all our
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covariates by subtracting the mean and then dividing the result by its standard error. We
implemented the BYM model in WinBUGS 128 using Monte Carlo Markov Chain
(MCMC) simulation, in which samples are generated from a posterior distribution given
observed values. We generated 200,000 iterations with the first 20,000 discarded as
“burn-in” values. The estimated mean relative risks and parameters from these samples
along with their corresponding 95% credible intervals were computed and mapped. To
ensure that our model converged the time series plots produced in WinBUGS were
visually checked and assessed. Significant high-risk areas were determined from 95%
credible intervals obtained with WinBUGS using our full Bayes BYM model. All of our
spatial analysis and graphing were completed with R statistical program 96 version 2.12.
4.4 Results
Our initial dataset consisted of 10,197 reports of chronic HCV-infected female
cases that were reported to DADE between 2004 and 2011. Of these, 1,686 (16.5%) cases
were missing geographical location information and were excluded from our analysis.
Our final data used for the spatial analysis consisted of 8,511 reports. Eighty-eight
percent (n = 7,473) met the clinical definition for a confirmed case and 40% were
assessed by either a RIBA or RNA test. The mean age of all the cases was 47.7 years.
None of the 46 counties had zero observed counts of HCV infection and counties with the
highest concentration of HCV reports matched up to major metropolitan areas in SC
(Figure 4.1).
The posterior means and Deviance information criterion (DIC) values from our
Bayesian hierarchical model are summarized in Table 4.1. From this table, we selected
the most parsimonious model with the smallest DIC value that converged. This final
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model contained our standardized main covariate variable of interest (total number of
drug treatment admissions) and potential confounders (race, education, proportion of
foreign-born residents and poverty). From this analysis, no significant associations
between total number of drug treatment admissions and HCV infection risk were
detected.
Unsmoothed raw SMR’s for HCV infection ranged from 0.11 to 3.26. However,
because these raw estimates can be very imprecise due to areas with small populations
and are affected by possible spatial correlation between disease risks in nearby areas, we
used our Bayesian model described above to produce smoothed estimates of disease risk.
Several counties with significant risks for HCV infection emerged (Figure 4.2) from this
analysis. Our smoothed relative risks ranged from 0.26 to 2.82 and high-risk areas for
HCV infection were observed in the coastal, midlands and Piedmont (mountain) regions
of the state. Based on our computed credible intervals from the BYM model, nine out of
the fourteen counties with an SMR >1, were statistically significant. Specifically, the
counties of Charleston, Darlington, Florence, Georgetown, Greenville, Horry, Oconee,
McCormick and Richland showed a significant high risk for HCV infection. The socioeconomic characteristics of these areas are summarized in Table 4.2. Compared to the
per capita income of $33,388 from 2012 129 for the entire state, four of the nine counties
had lower per capita incomes. Three counties (McCormick, Georgetown, Oconee) were
federally designated rural counties whereas the remaining counties were counties with
metropolitan centers. Of note, McCormick county exhibited the highest risk for HCV
infection (SMR=2.82) even after the data has been spatially filtered. This county also had
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the largest percentage of people of all ages living in poverty and the lowest percentage of
persons, 24 or older, with at least a college degree.
4.5 Discussion
We investigated the spatial epidemiology of HCV infections in South Carolina
(SC) as reported to disease surveillance between 2004 and 2011 using Bayesian
smoothing techniques. The results revealed that there is substantial variation in HCV
infection risk among the counties in SC and several of these counties were identified as
high-risk areas. These high-risk counties were a mixture of metropolitan and rural areas
distributed across the state. We did not find a significant relationship between number of
drug abuse treatment admissions reported in these counties and the HCV disease risk.
Additionally, we detected no relationship between HCV risk and confounding covariates
for which we adjusted in the BYM model.
Even though it has been well established that injecting drug use (IDU) is a leading
risk factor for HCV infection in developed countries, the number of drug abuse treatment
admissions in our Bayesian model did not explain the observed spatial variations in HCV
infections in SC. One explanation to this finding is that our aggregated counts of drug
abuse treatment admissions may not accurately reflect the extent of illicit drug use within
counties in SC. Since only publicly funded treatment centers report their data to
DOADAS, data from privately funded treatment centers are not included in these counts.
Furthermore, the treatment population represented in the DOADAS data set may not be
representative of all patients undergoing drug abuse treatment in SC. Lastly we could not
confirm if the this data comprised of only injector admissions.
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Yet, the fact that there was little change in the SMR’s after adjusting for potential
confounders (race, percent foreign born, education and poverty) and applying smoothing,
is an important observation in itself. This implies that there are other unobserved factors
that might be account for the high HCV prevalence in these areas and will require further
investigation. Up until recently, HCV infection related to IDU risk behavior was
understood to occur more in metropolitan centers as it is where drug trade is high and
readily available. However this notion is quickly changing. Three (33%), out of the nine
high-risk counties we identified were federal designated rural counties which,
corresponds to recent reports of an emerging HCV epidemic in rural and suburban
communities within the US 1, 98, 112. It is believed that this emerging problem may be
related to the national opioid epidemic seen largely in young injectors in nonurban areas
130, 131

.
The interpretation of our findings must also consider some weaknesses. First,

since small area analysis are ecological approaches, results obtained from this aggregated
levels of observation cannot be used to make assumptions regarding individual risks as
the result may not hold true at individual levels. Secondly, the geographic resolution at
which this study was carried out may have impacted our results, as aggregating data to
different areal arrangements (e.g. census or neighborhood tracts) may lead to different
results which may affect the interpretation of our findings 127. Another limitation to
consider is the fact that about 16% of all the HCV cases reported for study period were
excluded because of missing location data. These exclusions may have impacted the
observed HCV prevalence. Lastly, the HCV surveillance cases used here are a mixture of
asymptomatic individuals with risk factors who have been screened for disease and those
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showing signs of chronic liver disease. Therefore, it is likely that the data to some extent,
may reflect screening practices and initiatives rather than true prevalence or incidence of
HCV infection in various regions 116.
Taken these limitations into account, we were able to identify counties in SC with
significant HCV infection risks that warrant further investigations. The characteristics of
these significant high-risk areas described here should also motivate more targeted
prevention efforts to be undertaken within the state of South Carolina. Even though we
were unable provide a reasonable explanation as to why McCormick county exhibited an
unusually high SMR, this finding warrants further investigation by public health officials
in order to understand the underlying cause(s) for this observation.
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Table 4.1- Final Besag,York and Molli

(BYM) model for reported female cases of hepatitis
C virus (HCV) infection, South Carolina, 2004-2011, posterior means and 95% credible interval
Parameter

Posterior mean

95 % Credible Interval

Total number of Drug abuse
treatment admissions
Proportion White

1.01
1.00

0.97-1.05
0.97-1.04

Proportion aged ≥ 25 years
with at least a college degree
or higher

1.02

0.99-1.06

Proportion of foreign
residents

0.97

0.95-1.00

0.98
Included covariate
None
Drug
Drug, White,
Foreign, Poverty,
Education

0.95-1.02
DIC
389.692
389.304

Proportion of all ages living
below poverty
Model
1. Unadjusted
2. Adjusted for Drug

3. Adjusted for all covariates
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388.88

Table 4.2- Characteristics of counties in South Carolina with significant smoothed risks for hepatitis C infection
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County
SC
McCormick
Florence
Richland
Darlington
Georgetown
Oconee
Charleston
Horry
Greenville

Number
of HCV
cases
8,522
57
383
932
177
152
169
787
561
950

Average
female
population
(2004-2011)
2,063,083
4,659
66,662
165,940
35,513
29,097
33,661
160,182
100,095
194,834

Per
Capita
income
(2011)
33,388
27,509
34,450
36,347
29,355
38,403
31,964
41,656
29,148
37689

% Poverty
(2007)a
14.30
19.6
17.8
12.7
18.7
17.7
13.9
15.2
14
12.2

% White
(2007)
68.7
50.7
57.5
50
56.9
65.1
90.4
65.5
83
78

SMR= standardized morbidity ratio; HCV=hepatitis C virus; SC=South Carolina.
b
Proportion of people with age ≥ 25 with a college degree or more
a
Proportion of people of all ages living in poverty in 2007.

%
Educatedb
23.5
14.9
20.6
36.6
17.1
22
21
36.7
21
29.1

%
Foreign
born
residents
4.4
1.6
2.4
5.1
1.6
3.1
3.3
5
6.2
7.8

Number of
drug abuse
treatment
admissions
(2005-2011)
68,010
88
1,913
4,455
1,651
682
1,420
5,273
2,757
7, 001

Smoothed
SMR
2.8
1.44
1.34
1.31
1.28
1.24
1.19
1.17
1.15
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Figure 4.1 Map of South Carolina showing raw counts of reported female cases of hepatitis C infection per
county, 2004-2011.
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Figure 4.2 Standardized morbidity ratios (SMR’s) and smoothed relative risks for reported hepatitis C virus
female cases of hepatitis C viral infections in South Carolina, 2004
2004-2011
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Figure 4.3 95% credible intervals of the relative risks obtained from BYM model

CHAPTER 5
PREGNANCY OUTCOMES IN WOMEN INFECTED WITH HEPATITIS B OR C VIRUS
5.1 Abstract
The objective of this study was to estimate the association between maternal
hepatitis B or C (HBV, HCV) infection status during pregnancy and preterm birth, small
for gestational age (SGA), low birth weight (LBW) and neonatal intensive care unit
(NICU) admission. We utilized data from a cohort of singleton pregnancies from women,
aged 15-49, whose births were recorded in the South Carolina birth registry between
2004 and 2011. Restricting our analysis to women who contributed more than one
pregnancy over the study period, we used logistic regression to analyze pregnancy
outcomes after a subsequent pregnancy after considering infection status in a prior
pregnancy. A total of 438,208 singleton pregnancies in women aged 15-49 years were
recorded in the SC birth registry over the 8-year study period. Of these, 211,457 (48.3 %)
pregnancies were from women who contributed two or more consecutive pregnancies
prospectively and 95,291 (21.7%) pregnancies were subsequent pregnancies that were
used for the analysis. Among pregnancies that were studied, 276 (0.29%) were HCVinfected and 236 (0.25%) were HBV-infected. After adjusting for known confounders
babies born to HCV-infected mothers whose status changed from a non-diseased state in
their previous pregnancy, to a diseased status in their subsequent pregnancy had higher
odds of LBW (OR=2.07, 95% CI 1.28- 3.37) after being compared to non-infected cases.
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No increase in odds was identified for HBV mothers. Our results supports an association
between LBW and HCV infection, specifically for mothers who transitioned from a noninfected status state in their previous pregnancy, to an infected status during their
subsequent pregnancy in our study.

5.2 Introduction
Approximately one third of the world’s population have been infected with
Hepatitis B virus (HBV) and between 130-170 million, 2-3% of the world’s population,
are chronically infected with hepatitis C virus (HCV) 82. Together, both infections
constitute a major global health problem as they cause significant liver-related morbidity
and mortality among those infected 60, 80. In low endemic regions, such as the United
States (US), HBV and HCV affect a considerable proportion of women. Based on data
from the National Health and Nutrition Examination Surveys (NHANES), chronic HBV
infection affects about 0.19% of women whereas approximately 1.1% are chronically
infected with HCV 12, 84.
There have been varied reports on the prevalence of HCV and HBV infection in
pregnant women and in women of childbearing age. Within the US, around 0.06 to 1% of
pregnant women are said to be infected with HCV 28, 44, 48, 50, 132 whereas 0.09% to 5.7 %
of antenatal women are infected with HBV26, 28, 44, 48, 93, 133. Even though these numbers
appear to be small, they correspond to several thousands of HCV- and HBV-infected
pregnant women who deliver at risk babies in the US annually. For instance, in one study
that used birth registry data from 22 US states, it was reported that about 16,608 women
who had babies in 2006 were HBV-infected 26.
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The literature on how pregnancy outcomes are impacted by these viral infections
remains inconclusive. Current knowledge linking preterm birth, small for gestational age
(SGA), low birth weight (LBW) and neonatal intensive care unit (NICU) admission to
maternal HBV or HCV infection is controversial, as these results have been mixed. While
some studies have found an increased risk for preterm birth 44, 45, 47, SGA 44, 50, LBW 44, 48,
50

and neonatal intensive care unit (NICU) admission50 50in HCV- and HBV-positive

women, other studies 28, 44, 50, 51, 57 have found differently. For example, three studies 45, 55,
134

that examined preterm births found no increased risk among mothers who tested

positive to hepatitis B surface antigen (HBsAg) whereas two other studies 45, 47 reported
an increased risk for preterm births among HBsAg positive women. With the exception
of a few papers 28, 44, 50, most studies used small sample sizes, which limited their
generalizability. Even more importantly, ICD-9 codes were used to ascertain disease
exposure status and/or other potential confounders and it is likely biases from residual
confounding and inaccurate exposure assessment were introduced into these studies.
Hence, more information from large, population studies that overcome some these
limitations are needed to better understand how being HCV- or HBV-positive during
pregnancy may impact birth outcomes. Additionally, the conventional statistical
approaches used in previous studies 44, 50 have ignored correlations resulting from the
clustering of multiple pregnancies from the same mother. Also, the fact that infected
cases may belong to groups of “recently diagnosed” or ‘chronic carrier’ cases have been
overlooked. Assuming that there is a carryover effect from a prior infected pregnancy or
ongoing treatment, the risk of an adverse pregnancy outcome may be different for newly
infected cases compared to those cases with a prior infected pregnancy.
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In the present study, we sought to estimate the association between maternal
HBV or HCV status with preterm birth, SGA, LBW and NICU admission among a
retrospective cohort of antenatal women from the South Carolina (SC) birth registry data.
Our approach was to assess if there was a difference in the risk (which is equal to the
odds given that these outcomes are rare) for an adverse pregnancy outcome for “recently
diagnosed” and ‘chronic carrier’ cases of maternal HCV or HBV infection compared to
subsequent non-infected pregnancies.
5.3 Methods
This secondary data analysis utilized data from the SC birth registry, where data
pertaining to all live births are recorded, the South Carolina (SC) Health Electronic
Surveillance System (CHESS), a database that contains surveilled female cases (probable
and confirmed) infected with HCV or HBV, and the Department of Alcohol and Other
Drug Abuse Services (DOADAS), which contains patient level information on treatment
admissions for substance abuse. Detailed information on the methods used to link birth
registry data to CHESS is reported elsewhere 93, 113 Furthermore, an assessment of the
concordance between these two data sources for maternal HBsAg infection status showed
that the agreement was moderate and that our sensitivity for finding HBsAg positive
cases in the birth registry was enhanced through the linkage 93.
Approval for this study came from the Institutional Review Boards for the SC
DHEC, the University of SC Office of Research Compliance and the SC Budget and
Control Board, Office of Research and Statistics (ORS) Data Oversight Committee. From
the birth registry data, we selected all singleton pregnancies from women, aged 15-49,
whose births were recorded between 2004 and 2011. After linkage to CHESS we
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additionally linked the birth registry/CHESS file to substance abuse treatment admissions
data from DAODAS. All publicly funded drug abuse treatment facilities in SC are
required to report patient information recorded at the time of intake to DOADAS.
Reported data elements include the patient’s primary or secondary substances of abuse,
the route of intake, age, gender, race, county of residence, type of treatment and prior
treatment admissions. Since information on alcohol use that is recorded on the birth
certificate is known to be unreliable 79, linkage to DAODAS enabled us to obtain
additional information on the alcohol and drug abuse/use history of subjects in the birth
registry. We only used treatment admissions data for SC female residents that occurred
from 2005 to 2011, as data from 2004 was unavailable for linkage.
Exposure definition
Maternal HCV or HBV status was ascertained from the linked CHESS/birth
registry data. The case definitions used to describe probable or confirmed cases of HCV
and HBV from CHESS have been described elsewhere in detail 93, 113. Our exposed
cohort was made of singleton pregnancies where the mother was known to be either HBV
or HCV positive prior to or during that observed pregnancy. We considered a case
positive if it was reported to CHESS prior to or during the year of childbirth.
Additionally, we also included positive cases from the birth data that were not reported to
CHESS as being HCV or HBV positive. Pregnancies that occurred before a notification
was made in CHESS or were not positive on the birth certificate were considered
negative and these pregnancies made up our non-infected cohort. Any pregnancies that
had an unknown HBV or HCV infection status were excluded.
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Pregnancy outcomes
We had four main outcomes of interest in this study and these were preterm birth,
low birth weight (LBW), small for gestational age (SGA) and neonatal intensive care unit
(NICU) admission. A recent validation of the SC birth certificate data showed that
obstetric estimate of gestational age, birth weight in grams and NICU admission were
among the variables with excellent agreement and sensitivity 135. Obstetric estimation of
gestational age has also been previously validated in the US birth registry data 136.
Preterm birth was ascertained from obstetric estimate of gestational age in weeks and
infants were considered preterm if they were born before 37 weeks. Any births with a
gestational age of ≤ 20 weeks were excluded from this study, as these births are often not
viable. We defined LBW as < 2,500 grams at the time of birth. SGA, a measure of fetal
growth restriction, was assessed as birth weight below the 10th percentile for gestational
age according to fetal sex on standardized weight charts developed by Alexander et al.
137

.

Maternal characteristics
Maternal covariates of interest were abstracted from the linked birth
registry/DAODAS file and these were included as potential confounders in our analysis.
We categorized our potential confounders into two main groups: socio-demographic
confounders and risk factor confounders. These potential confounders were selected
based on a review of the literature, biological plausibility and on whether or not they
were statistically significant in our univariate analysis. Socio-demographic confounders
included maternal age (<20 vs. 20-29 vs. ≥ 30 years), race/ethnicity (non-Hispanic white
vs. non-Hispanic Black vs. Hispanic vs. Other), education (< high school vs. high school
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vs. beyond high school), Women and Infant Care (WIC) program participation (yes vs.
no), payer source (Medicaid vs. private insurance vs. self pay vs. other) and adequacy of
prenatal care (inadequate vs. intermediate vs. adequate vs. adequate plus vs. unknown).
Adequacy of prenatal care was determined by using the revised graduated index proposed
by Kotelchuck, which has been found to describe the level of prenatal care utilization
among high-risk groups quite well 138, 139.
All of the risk factor related variables were dichotomized as yes vs. no. Risk
factor confounders consisted of maternal tobacco use during pregnancy, presence of a
sexually transmitted infection (STI), previous adverse outcome, other morbidities and
history of alcohol or drug abuse. The presence of an STI was assessed as presence of any
of the following infections during pregnancy; syphilis, gonorrhea, chlamydia and genital
herpes. For previous adverse outcome, which also reflected the reproductive history of
each case, we created a composite variable to represent a previous preterm birth or
previous poor pregnancy outcome to include a perinatal death, small-for-gestational age
and intra uterine growth restriction. By including prior adverse birth outcomes in the
model, we focus on the risk that is related to a change of the infection status. Other
pregnancy morbidities were considered present if any of the following conditions were
checked on the birth certificate: pre-pregnancy hypertension, pre-pregnancy
hypertension, gestational hypertension, fertility treatment, previous cesarean, gestational
diabetes and vaginal bleeding. Women were classified as having a history of drug or
alcohol abuse if they were found in the DAODAS database and reported alcohol, cocaine,
methamphetamine, opiates, sedatives or stimulant use as either their primary, secondary
or tertiary substance of abuse at the time of treatment admission and also determined their
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primary route of drug of use. Lastly, we considered the parity of the pregnancies and
interval between their prior and subsequent pregnancy as continuous variables in our
analysis.
Statistical analysis
Our analysis was restricted to a subset of women who had two or more
subsequent pregnancies captured in our dataset over the eight-year study period. From
this group, we assessed pregnancy the incidence of preterm birth, LBW, SGA and NICU
admission as it pertained to maternal HCV and HBV infection (Figure 5.1). We
categorized our exposure group into three levels based on their exposure status at the time
of their initial and subsequent pregnancy. Our reference group consisted of those
pregnancies that had no disease in their initial and subsequent pregnancy (non-diseased).
Our “recently diagnosed” group included those mothers who were without disease at the
time of their initial pregnancy and then positive at the time of their subsequent
pregnancy. Lastly, our ‘chronic carriers’ disease group, was defined as all those who had
HBV or HCV disease in both their initial and subsequent pregnancy.
We used the Pearson Chi-square (χ2) statistic to compare socio-demographic and
risk factor variables between non-infected and infected pregnancies. Descriptive statistics
were presented as number (percentage) for categorical variables and in mean (range) for
continuous variables such as parity and interval between pregnancies. As we were only
assessed outcomes for one time point (t=1), only one pregnancy was contributed by each
woman to the dataset, thus, we had no issue with clustering from multiple pregnancies
from women who contributed several pregnancies over the study period.
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Multivariable logistic regression model using PROC GENMOD in SAS, was used
to model the effect of ‘recently diagnosed’ and ‘chronic carrier’ infections of HCV and
HBV disease on preterm birth, LBW, SGA and NICU admission. We included our main
exposure of interest as categorical variable with three levels (non-diseased vs. ‘recently
diagnosed’ vs. ‘chronic carrier’) into our regression model with non-diseased group
serving as our baseline reference group. In order to see how our parameter estimates
changed, with the addition of confounding variables to the model, we used a forward
stepwise modeling approach that entered a block of variables at a time. Consequently,
three models were fitted for each outcome, per disease (HCV or HBV). Since past
reproductive history is strongly associated with birth outcomes 140 our crude model
included our main covariate adjusted for previous adverse pregnancy outcome, parity and
interval between initial and subsequent pregnancy. In this first model, the unadjusted
odds ratios (ORs) were calculated for the association between each outcome and our
main covariate variable. Next, the ORs in the second model were additionally adjusted
for socio-demographic confounding variables. Finally, the ORs in our fully adjusted
model included risk factor variables and all the variables contained in second model. All
statistical tests were performed using SAS (version 9.3, SAS institute, Inc.).
5.4 Results
There were 438,208 singleton pregnancies in women aged 15-49 years recorded
in the SC birth registry over the 8 study years, 2004- 2011. After excluding cases, which
were co-infected with both HCV and HBV (n=30), 438,178 pregnancies remained. Of
these, 211,457 (48.3 %) pregnancies were from women who contributed two or more
consecutive pregnancies prospectively during the observation period. At the time of
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subsequent pregnancy (t=1), we had 95, 291 (21.7%) pregnancies (Figure 5.1). Among
the pregnancies that were studied, 276 (0.29%) were HCV-infected and 236 (0.25%)
were HBV-infected. Removing pregnancies with missing SGA (n=31), LBW (n=7),
payment source for delivery (n=646), WIC usage (n=6), parity (n=45), race (n= 195),
maternal education (n=321) and tobacco use during pregnancy (n=66) left a total of at
least 93, 814 pregnancies for our multivariate analysis.
Table 5.1 summarizes the differences between HCV-, HBV- and non-infected
pregnancies in terms of selected socio-demographic and risk factor characteristics at the
time of a subsequent pregnancy. Compared to mothers with non-infected pregnancies,
HCV-infected mothers were young adults; and were more likely to be of Black nonHispanic race, participate in WIC, use Medicaid payment for delivery, smoke during
pregnancy and to receive a lower level of prenatal care. They were also more likely to
have a history of alcohol and drug abuse. HBV-infected mothers were also young adults.
They were more likely to be of Hispanic race, have at least a high school education,
participate in WIC, use Medicaid as a source of payment for delivery and have tested
positive for an STI.
When we compared the frequencies of adverse pregnancy outcomes between noninfected pregnancies and infected pregnancies (Table 5.2), those that were HCV-infected
were more likely than non-infected pregnancies to have a LBW, small for gestational age
and an admission to the NICU unit. These significant differences were not observed for
HBV infections.
Crude and adjusted OR’s for the association between preterm birth, NICU
admission, LBW, SGA and HCV or HBV infection are summarized in Tables 5.3 and
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5.4. Our analysis revealed a significant relationship between delivering a baby with low
birth weight and maternal HCV infection among the ‘recently diagnosed’ group. After
adjusting for potential confounders, HCV-infected cases who went from a non-diseased
state in their previous pregnancy, to a diseased status in their subsequent pregnancy had
higher odds of LBW (OR=2.07, 95% CI 1.28- 3.37) after being compared to non-infected
cases. After adjusting for risk factors, the association for preterm birth and SGA related
to HCV-infection in the ‘recently diagnosed’ group became marginally significant
respectively (OR= 1.85, 95% CI: 0.95-3.6, p-value=0.06; and OR=1.85; 95% CI: 0.953.60, p-value =0.07). We found no significant associations for HCV infection and NICU
admission. Likewise, when we examined the models for HBV-infected cases, we found
that being HBV-infected, be it a ‘recently diagnosed’ or a ‘chronic carrier’ case, did not
confer an additional risk for LBW, SGA, preterm birth and NICU admission.
5.5 Discussion
Our analysis of data from the SC birth registry revealed that being a ‘recently
diagnosed’ HCV-infected case was independently associated with LBW but not preterm
birth, SGA and NICU admission. We also found no significant associations between
HBV infection and these outcomes.
As I have already noted, the few studies of HCV infection and adverse birth
outcomes have provided controversial results. Two large population-based US studies
found that HCV-infected mothers were at an increased risk of delivering LBW and SGA
babies and babies who were admitted into NICU 44, 50. Conversely, findings from Haider
et al. 56, Jaffery et al.57 and Hillemanns et al. 52 showed that being HCV-infected during
pregnancy is not associated with delivering preterm or LBW babies. What must be noted
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in these latter studies is that they were conducted in antenatal clinics that attended to
‘high-risk’ prenatal clients. Therefore, selection bias and use of small sample sizes could
have affected their results. Our analysis drew from a large population-based cohort of
pregnant women and assessed the change in infection status as exposure. While our
approach to analysis was different from that used in previous studies, our overall finding
with HCV infection is consistent with the findings of Connell et al. 44 and Pergam et al.
50

, who both used birth registry data.
We were surprised not to detect a difference in risk for those ‘chronic carrier’

patients, that is, those that had a positive HCV or HBV status in their initial and
subsequent pregnancies. Yet, no such significant associations were revealed in our
analysis. One likely reason is that, we did not have a sufficient number of events in this
group to be able to detect a significant effect. Another plausible explanation could be that
after the discovery of their infection status, patients may have undergone antiviral therapy
to control and stabilize their viral disease before conceiving again. Some studies that
demonstrated improved outcomes in infected individuals who have undergone interferon
therapy and are without persistent viremia 141, 142. Therefore, if these patients had low
viremia in their subsequent pregnancies it is unlikely the disease had any impact on their
pregnancy outcome. Unfortunately, since our data did not include any information about
HCV or HBV viremia or viral load during pregnancy, we had no way of confirming this
speculation.
Earlier studies on HBV infection and birth outcomes have found significant risks
for preterm birth 45, 47 and SGA 44 whereas other studies 44, 45, 55, 134 that looked at preterm
births and LBW found no increased incidence among mothers who tested positive to
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HBsAg. This study demonstrated a null effect for preterm birth, SGA, LBW, NICU
admission and HBV infection. Though our results differ from the earlier non-US studies
that have come from small centers, our finding for HBV is similar to the only other US
study that used birth registry data. With the exception of SGA, Connell et al. found no
significant risks associated with being HBV infected during pregnancy. Even though both
virus primarily infect hepatic cells, they are virologically distinct and display numerous
clinical differences 143. For example, most adults infected HBV are able to clear their
infection spontaneously, resulting in lifelong protective immunity whereas 60-80% of
adults with HCV fail to control the infection and develop chronic disease 143. A plausible
explanation to this observation may lie in the divergent immune responses produced by
HCV and HBV. Studies have already linked circulating pro-inflammatory cytokines from
maternal innate and adaptive immune responses to adverse pregnancy outcomes 144-146.
Accumulating evidence suggests that there is a lack of interferon response during HBV
acute infection resulting from the inactivation of various pathways that will normally
induce interferon and cytokine production147. In other words, HBV ‘evades’ the innate
immune response by not inducing it to act whereas HCV induces a strong innate and
adaptive immune response 148, 149 which leads to interferon and cytokine production
during the initial stage of infection. From this knowledge, it can be gathered that the
‘stealth’ of HBV may perhaps be the reason why no effect was seen for HBV infection.
Our study has limitations that should be acknowledged. First, our approach to
this analysis only included outcomes after the subsequent pregnancies that were observed
prospectively. These pregnancies may not necessarily have be the second pregnancy of
that mother as its possible they had other pregnancies that were not captured in our
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observation window. We acknowledge the fact that our use of the term ‘‘recently
diagnosed’’ especially for HCV-infected cases does not truly reflect ‘new cases’ of
infections. Rather, these are past or present infections that went undiagnosed for years.
The fact that our infected pool of cases was largely made up of chronic cases reported
surveillance underscores this point. In our data set, 49% and 42% of “recently
diagnosed” HBV and HCV cases had their diagnosed within 2 years after an initial
uninfected pregnancy. Among these “recently diagnosed” pregnancies, the frequency of
preterm birth and LBW were consistently higher for HCV infected cases compared to
non-infected cases whereas the frequency of SGA was higher among HBV infected cases
compared to non-infected cases. In addition, because there is no universal screening for
HCV, the HCV-positive cases in our data were most likely identified through provider
initiated risk-based screening. Consequently, the HCV cases here are a mixture of those
who exhibit high risk factors and those experiencing symptoms of early liver disease.
Lastly, another limitation to consider is the fact that our data contained no information on
hepatitis viremia (viral load) or treatment status. Therefore, we were not able to assess
these variables in our study. We also had no information on the HIV/AIDS status of
these mothers thus we were unable to adjust for the effect of this disease in our analysis.
In spite of these limitations, there are several strengths to this study. Our approach
to analysis used here enabled us to assess if the risks for ‘newly diagnosed’ and ‘chronic
carrier’ cases of disease were different. Also, by linking birth data to surveillance data,
we were able to improve our sensitivity for case finding in the birth data, thus the
potential for misclassification of maternal disease status was greatly reduced. Further
linkage to substance abuse treatment data allowed us to ascertain maternal drug and
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alcohol use. These are variables that would otherwise not be available in the birth
certificate data. Lastly, our sample of subsequent pregnancies was comparable to all the
singleton births (see Appendix D) that occurred in SC over the study period. If we
consider the state of South Carolina as a sampling unit of Southern US, our data may well
be representative of the demographic composition of women in residing in this region of
the US. Therefore our results are generalizable to populations in the south with similar
demographics. .
In summary, our data supports an association between LBW and HCV infection,
specifically for mothers who were ‘recently diagnosed’ in our study. These findings have
some implications for HCV-positive women entering into prenatal care. LBW is an
important risk factor for infant mortality 150, 151 and from a practice point of view, this
information is useful for providers to advise infected expectant mothers on the potential
risk to their baby. Although universal screening for HCV infection during pregnancy is
not currently recommended in the US, given our findings, additional steps, such as
improving nutrition and receiving adequate prenatal care can be taken to help reduce the
effect of this disease on pregnancy outcome. The current interferon therapy for HCV
infection is not indicated for pregnant women and there is no vaccine to prevent perinatal
HCV infection, however that may soon change. When that time arrives, linkage to care
during pregnancy may help reduce the risk of this disease on low birth weight. But until
such a time, future studies should consider investigating how a patient’s viremia affects
pregnancy outcomes. Finally, more population-based studies with more power are needed
to determine if ‘chronic carriers’ of disease poses a higher risk.
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Table 5.1- Characteristics of HCV-infected and HBV-infected pregnancies in South Carolina,
2004 -2011

Socio-demographic
variables
Age in years, median
(range)
< 20 years
20-29 years
≥ 30 years
Race/ethnicity
non-Hispanic White
non-Hispanic Black
Hispanic
Other
Maternal education
< High school
High school
Beyond high school
Did mother use WIC
No
Yes
Unknown
Payment source for
delivery
Medicaid
Private Insurance
Self-pay
Other
APCU indexe
Inadequate
Intermediate
Adequate
Adequate plus
Unknown

Non-infected
number (%)
n=(94, 870)

HCV+
number (%)
(n= 275)

26 (15 - 49)
6556 ( 7)
58467 (62)
29757 (31)

27 (17 - 41)
14 ( 5)
164 (60)
97 (35)

P-valueb

0.006c
0.24

HBVa +
number (%)
(n=235)

27 (17-43)
11 ( 5)
134 (57)
90 (38)

<.0001
8669 ( 9)
52306 (55)
32064 (34)
1546 ( 2)

12 ( 4)
187 (68)
69 (25)
7 ( 3)

20 ( 9)
60 (26)
103 (44)
51 (22)

77 (28)
90 (33)
106 (39)

0.0063
66 (28)
77 (33)
91 (39)
0.308

0.029
44516 (47)
48624 (51)
1634 ( 2)

0.001c
0.047

<.0001

0.0013
21938 (23)
24965 (26)
47558 (50)

P-valueb

105 (38)
163 (59)
7 ( 3)

96 (41)
134 (57)
5 ( 2)
0.05
<.0001

49508 (52)
35296 (37)
5947 ( 6)
3385 ( 4)

182 (66)
71 (26)
10 ( 4)
10 ( 4)

141 (60)
66 (28)
16 ( 7)
9 ( 4)
<.0001

20309 (21)
6635 ( 7)
27826 (29)
39464 (42)
546 (<1)

92 (33)
25 ( 9)
64 (23)
93 (34)
1 (<1)

85

0.06
67 (29)
19 ( 8)
65 (28)
82 (35)
2 (<1)

Table 5.1- Characteristics of HCV-infected and HBV-infected pregnancies in South Carolina,
2004 -2011 (cont’d.)

Non-infected
HCV+
number (%) number (%)
n=(94, 870)
(n= 275)
Risk factor variables
Maternal smoking during
pregnancy
No
Yes
Maternal STI during
pregnancyd
No
Yes
Previous adverse
outcome
No
Yes
Risk factors present in
pregnancy
No
Yes
History of alcohol abusef
Yes
No
History of drug usef
No
Yes
Primary route of drug use
Injection or
intramuscular
Other
Interval between
pregnancies, median
(range), years
Parity, median (range)

P-valueb

HBVa +
number (%)
(n=235)
P-valueb

0.106

<.0001
82282 (87)
12432 (13)

150 (55)
125 (45)

88094 (93)
6686 ( 7)

251 (91)
24 ( 9)

84739 (89)
10041 (11)

235 (85)
40 (15)

64590 (68)
30190 (32)

180 (65)
95 (35)

93125 (98)
1655 ( 2)

237 (86)
38 (14)

92383 (97)
2397 ( 3)

196 (71)
79 (29)

206 (88)
28 (12)
0.27

0.016
209 (89)
26 (11)
0.688

0.033
212 (90)
23 ( 10)
0.338

0.39
154 (66)
81 (34)

<.0001

<.0001
223 (95)
12 ( 5)

<.0001

0.03
224 (95)
11 ( 5)

<.0001
107 ( 4)
2290 (96)

29 (35)
51 (65)

11 (100)

2 (<1-7)
1 (1-22)

3 (<1-7)
2 (1-13)

2 (<1-7)
1 (1-8)

CHESS=South Carolina Health Electronic Surveillance System; BC = birth certificate (registry) data; HBV=
hepatitis B virus; HCV=hepatitis C virus, STI= sexually transmitted infections; WIC=women, infant and
children nutrition program, APCU= adequacy of prenatal care utilization.
a
These include 37 pregnancies confirmed in CHESS as acute HBV cases.
b
Pearson Chi-square test
c
Kruskall Wallis test
d
STI infections include presence of either chlamydia, gonorrhea, syphilis or genital herpes infection for that
pregnancy
e
Adequacy of prenatal care utilization index as defined by Kotelchuck (1994)
f
Data from Department of Drug, Alcohol and Other Drugs. Indicates if patient has received treatment
services for drug or alcohol addiction
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Table 5.2 - Frequency of adverse birth outcomes at the time of a subsequent pregnancy by exposure to viral hepatitis: South Carolina, 20042011.
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Adverse birth outcome
Preterm birth
No
Yes
Low birth weight, grams
No
Yes
Small for gestational age
No
Yes
Newborn Admission to
NICU
No
Yes

HBVb +
(N =235)

Non-infected
(N = 94, 870)

HCV +
(N = 275)

85567 (90)
9213 ( 10)

238 (87)
37 (13)

0.037

211 (90)
24 (10)

0.79

87933 (93)
6840 ( 7)

240 (87)
35 (13)

0.002

217 (92)
18 ( 8)

0.95

86009 (91)
8740 ( 9)

235 (85)
40 (15)

0.0093

208 (89)
27 (11)

0.46

90325 (95)
4455 ( 5)

256 (93)
19 ( 7)

0.08

217 (92)
18 ( 8)

0.03

P value

a

P valuec

NICU= Neonatal intensive care unit. CHESS= South Carolina Health Electronic Surveillance System; BC = Birth certificate (registry)
data; HCV=hepatitis C virus; BC = Birth certificate (registry) data; HBV= hepatitis B virus.
a
Pearson Chi-square test comparing HCV infected pregnancies to non-infected pregnancies.
b
These include 37 pregnancies confirmed in CHESS as acute HBV cases.
c
Pearson Chi-square test comparing HBV infected pregnancies to non-infected pregnancies
*Frequencies may not equal the total N shown because of missing numbers not shown in table.

Table 5.3- Multivariate logistic regression analysis of subsequent pregnancy outcomes after maternal hepatitis C viral infection.
Model 1a

88

SGA (n=93,829)
Non disease- non disease (n=93,557)
Newly diagnosed (n=124)
Chronic carriers (n=148)
AIC
Low birth weight (n=93,851)
Non disease- non disease (n= 93,579)
Newly diagnosed (n=124)
Chronic carriers (n=148)
AIC
Preterm (n=93,856)
Non disease- non disease (n=93, 584)
Newly diagnosed (n=124)
Chronic carriers (n=148)
AIC
NICU Admission (n=93,856)
Non disease- non disease (n=93, 584)
Newly diagnosed (n=124)
Chronic carriers (n=148)
AIC

Model 2b

Model 3c

OR (95% CI)

P-value

OR (95% CI)

P-value

OR (95% CI)

P-value

1.00
1.95 (1.22-3.13)
1.39 (0.86-2.26)
57704

0.0051
0.17

1.00
2.09 (1.29-3.36)
1.41 (0.87-2.31)
55362

0.0024
0.158

1.00
1.51 (0.93-2.45)
1.10 (0.67-1.80)
54892

0.09
0.68

0.0001
0.64

1.00
2.80 (1.73-4.52)
1.17 (0.65-2.10)
45071

<.0001
0.59

1.00
2.07 (1.28-3.37)
0.84 (0.46-1.53)
449595

0.0030
0.58

0.06
0.92

1.00
1.66 (1.01-2.73)
1.03 (0.60-1.75)
55402

0.04
0.91

1.00
1.47 (0.89-2.43)
0.83 (0.48-1.4)
55060

0.12
0.51

0.15
0.54

1.00
1.63 (0.85-3.15)
1.20 (0.60-2.38)
34215

0.13
0.59

1.00
1.39 (0.72-2.69)
0.98 (0.49-1.95)
33965

0.32
0.95

1.00
2.51 (1.58-4.00)
1.14 (0.64-2.03)
47990
1.00
1.58 (0.97-2.56)
1.02 (0.60-1.72)
58866
1.00
1.6 (0.83-3.06)
1.23 (0.6-2.4)
35040

SGA= small for gestational age; NICU=neonatal intensive care unit; CI= confidence interval; AIC=Akaike information criterion.
a
Model 1: Adjusted for parity, previous adverse pregnancy outcome, interval between first and second pregnancy
b
Model 2: Model 1 + socio-demographic variables (age, insurance status, race, education, adequacy of prenatal care received, WIC status)
c
Model 3: Model 2 + risk factors (smoking , history of alcohol abuse, history of drug use, morbidity)

Table 5.4- Multivariate logistic regression analysis of subsequent pregnancy outcomes after maternal hepatitis B viral infection.
Model 1a

OR (95% CI)
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SGA (n=93,787)
Non disease- non disease (n=93,557)
Newly diagnosed (n=63)
Chronic carriers (n=167)
AIC
Low birth weight (n=93,809)
Non disease- non disease (n=93,579)
Newly diagnosed (n=63)
Chronic carriers (n=167)
AIC
Preterm (n=93, 814)
Non disease- non disease (n=93,584)
Newly diagnosed (n=63)
Chronic carriers (n=167)
AIC
NICU Admission (n=93,814)
Non disease- non disease (n=93,584)
Newly diagnosed (n=63)
Chronic carriers (n=167)
AIC

1.00
2.05 (1.08-3.93)
1.03 (0.66-1.73)
57656
1.00
1.28 (0.54-2.97)
0.88 (0.4-1.64)
47904
1.00
1.44 (0.70-2.94)
0.82 (0.47-1.42)
58821
1.00
2.05 (0.87-4.78)
1.43 (0.77-2.64)
35014

Model 2b

Model 3c

P-value

OR (95% CI)

P-value

OR (95% CI)

P-value

0.03
0.89

1.00
1.85 (0.95-3.6)
0.94 (0.55-1.58)
55318

0.06
0.82

1.00
1.85 (0.95-3.60)
0.92 (0.54-1.55)
54888

0.07
0.75

0.56
0.71

1.00
1.11 (0.47-2.62)
0.84 (0.43-1.56)
44990

0.81
0.58

1.00
1.07 (0.455-2.55)
0.81 (0.40-1.49)
44588

0.87
0.49

0.31
0.49

1.00
1.31 (0.63-2.71)
0.84 (0.47-1.46)
55360

0.46
0.52

1.00
1.29 (0.62-2.68)
0.81 (0.4-1.42)
55053

0.49
0.47

0.09
0.25

1.00
1.96 (0.83-4.60)
1.48 (0.79-2.75)
34192

0.12
0.21

1.00
1.82 (0.77-4.30)
1.488 (0.8-2.7)
33957

0.17
0.21

SGA= small for gestational age; NICU=neonatal intensive care unit; CI= confidence interval, AIC=Akaike information criterion.
a
Model 1: Adjusted for parity and previous adverse pregnancy outcome and interval between first and second pregnancy)
b
Model 2: Model 1 + socio-demographic variables (age, insurance status, race, education, adequacy of prenatal care received, WIC status)
c
Model 3: Model 2 + risk factors ( smoking , history of alcohol abuse, history of drug use, morbidity and presence of STI)
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Figure 5.1 Study design used for analyzing subsequent pregnancies in South Carolina, 2004-2011

CHAPTER 6
SUMMARY AND CONCLUSIONS
Descriptive studies
Both descriptive studies provided a characterization of the Hepatitis B and C virus (HBV,
HCV) mono-infection and HBV/HIV, HCV/HIV and HBV-HCV co-infections among
females in South Carolina. There was significant variation in the epidemiology of these
infections in SC. In the HBV descriptive study, we estimated the prevalence of HBsAg
among pregnant women to be 0.17% and found that HBV/HIV co-infection was
substantial. Approximately 9% of chronic HBV cases in the study period were coinfected with either HIV (4%) or HCV (5%). Chronic HBV/HIV co-infected cases were
more likely to be Black women from urban areas in SC, who reported heterosexual
contact as the main risk factor for HIV transmission. These HBV co-infected cases also
had low first CD4 counts after HIV diagnosis and there was a 9-year median time
between HIV diagnosis and a subsequent HBV diagnosis. Taken together, these findings
suggest that there are gaps in compliance with the recommended routine HBV screening
and immunization for HIV-infected persons. Additionally, the findings indicate a missed
opportunity for those with undiagnosed HBV to be put on appropriate medication that
would treat both HIV and HBV. Women between the ages of 20 and 49 reported the
highest frequencies of HBV infections and within the state, the largest proportion of acute
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HBV infections reported from the Northeastern region (Pee Dee) of the state. We also
found moderate agreement between CHESS and the birth registry data when we
compared the degree of concordance for HbsAg positive cases reported during
pregnancy. From these results we determined that disease surveillance of infections
diagnosed during prenatal screening needed improvement. Additionally, our findings are
suggestive to increase efforts to improve screening, reporting and prevention, especially
among black women.
In the HCV descriptive study we focused on describing the disease burden and
characteristics associated with HCV, HCV/HIV and HCV-HBV co-infection. Results
from this study revealed an emerging epidemic of HCV infections among young white
females between the ages of 15 and 25 years in recent years. However, a large burden of
HCV mono infection was still found in middle-aged white women. Four percent of cases
were co-infected with HCV/HIV and they were more likely to black, whereas 1% of
HCV cases were co-infected with HCV-HBV and they were more likely to be White.
These findings suggest a need for resources to be directed at improving screening and
prevention efforts among Black and White middle aged women and most especially, in
young persons between the ages of 15 and 25 years. Also because HCV risk behavior and
detailed race information were unavailable for analysis in our HCV surveillance data,
initiatives to fund and improve HCV case reporting data are warranted.
Spatial analysis of HCV infections
An investigation into the spatial epidemiology of HCV infections in SC showed
considerable differences in how HCV is distributed across the state. Our Bayesian spatial
analysis identified several counties as high-risk areas for HCV infection. These counties,
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namely Charleston, Darlington, Florence, Georgetown, Greenville, Horry, Oconee,
McCormick and Richland, represent a mixture of metropolitan and federally designated
rural areas. McCormick county exhibited the highest risk for HCV infection even after
the standardized morbidity ratio (SMR) had been spatially smoothed. This county also
had the largest percentage of people of all ages living in poverty and the lowest
percentage of persons, 24 or older, with at least a college degree. Our report of high HCV
risks seen in rural SC corresponds to other recent reports of an emerging HCV epidemic
in rural communities within the US which has been largely attributed to the increasing
number of injecting drug users (IDU) in these areas.
Even though we assessed drug treatment admissions data as potential explanatory
covariate for HCV infection in the spatial model, it did not explain the observed spatial
variation. This implies that other unobserved factors that might account for the high HCV
prevalence observed in these areas exists and will require further investigation. The
infection prevalence map based on our spatial analysis provides a visual representation of
how HCV disease is geographically dispersed. Information from the high-risk areas
identified can used for policy decision-making and taking public health action. In
addition, information from spatial and descriptive analysis can use to allocate resources
more efficiently to help prevent and reduce the spread on HCV disease within the state.
Birth outcomes study
Even though the estimated national prevalence of HCV and HBV infections in the
antenatal population may seem small, these prevalence correspond to several thousands
of infected women who deliver babies annually and therefore constitute a public health
problem. One important finding from our study of birth outcomes is that low birth weight
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is independently associated with HCV infection during pregnancy. Specifically, HCVinfected women who transitioned from a non-diseased status to a diseased status in their
subsequent pregnancy had significant higher odds of delivering babies that had a low
birth weight. We found no significant associations between HCV infection, SGA, preterm
birth and NICU admission. Also, no effect was detected for ‘chronic carrier’ women who
were positive for HCV infection in their initial and subsequent pregnancies. We also
found that being HBV-infected, be it a ‘recently diagnosed’ or ‘chronic carrier’ case, did
not confer an additional risk for LBW, SGA, preterm birth and NICU admission.
LBW is an important risk factor for infant mortality and from a practice point of
view this information is useful for providers to advise infected expectant mothers on the
potential risk to their baby. Additional population-based studies with more power are
needed to determine if ‘chronic carriers’ of viral hepatitis poses a higher risk and future
studies should consider investigating how a patient’s viremia affects pregnancy
outcomes.
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APPENDIX A.
SUMMARY OF LITERATURE REVIEW FINDINGS
Table A.1 Summary of literature review findings by epidemiologic study design and
location
Author, year published
and location
Study design
55

Lobstein et al., (2011)
Germany

Retrospective cohort

Statistical Analysis
T-test and Mann Whitney
test with Bonferroni
correction

Sample size
(Disease prevalence)
39a
(0.48%)

Elefsiniotis et al.,47 (2010)
Greece

Retrospective cohort

Logistic regression

70a
(3.8%)

Saleh-Gargari et al.,152
(2009)
Iran

Case-control

Multinomial logistic
regression

450a

Case-control

Logistic regression

1138a
(8.3%)

Case-control

Logistic regression

253a

Case-control

Not reported

1340a
(9.7%)

Case-control

Unpaired t-test, Mann
Whitney test

824a
(11.6%)

2 tailed t-test

23b
(8.0%)

Mantel-Haenszel stratified
analysis

506b
(0.2%)

Lao et al.,153 (2007)
China
45

Tse et al., (2005)
China
To et al.,154 (2003)
Hong Kong
Wong et al.,134 (1999)
Hong Kong
Haider et al.,56 (2009);
Pakistan

Case-control

Pergam et al.,50 (2008)
USA

PB retrospective
cohort

Jaffery et al.,57 (2005)
Pakistan

Case-control

Logistic regression

31b
(3.27%)

Jabeen et al.,51 (2000)
Ireland

Case-control

Not reported

26 c

Case-control

Mann Whitney test MH
chi-square test

35 d
(0.94%)

Hillemanns et al.,52 (2000)
Germany
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Table A.1 Summary of literature review findings by epidemiologic study design and
location (cont’d.)
Author, year published
and location
Study design
Connell et al.,44 (2011)
USA

Statistical Analysis

Sample size
(Disease prevalence)

Logistic regression

1458e, 999f ,
(0.09%) (0.06%)

PB retrospective
cohort

Reddick et al.,48 (2011)
USA

814e, 555f,
Case-control

Safir et al.,49 (2010)
Israel

PB retrospective
cohort

Logistic regression
749g
(0.4%)

Logistic regression

Abbreviations: US=United States, MV=multivariable; PB=Population-based; MH= Mantel-Haensel;
PCR=polymerase chain reaction; a HBsAg assessed with Elisa assay; b Elisa and PCR confirmed anti-HCV
test ; c HCV RNA positive; d RIBA confirmed anti-HCV test eClinically diagnosed HBV from ICD-9-CM
codes; fClinically diagnosed HCV from ICD-9-CM codes; g Anti-HCV or HBsAg positive cases

Table A.2 Summary of literature review findings by study outcomes

Maternal outcomes
Gestational diabetes
Premature rapture of membranes
Preterm premature rapture of membranes
Pre-eclampsia
Intrauterine growth restriction
Cesarean delivery
Perinatal outcomes
Preterm birth
Small for gestational age
Low birth weight
Neonatal jaundice
Apgar score (1 min)
Assisted ventilation
Spontaneous abortion
Congenital abnormalities
NICU admission
Still birth

Hepatitis B virus
N
(5)
(3)
(1)
(5)
(1)
(2)
(5)
(3)
(2)
(2)
(3)
(1)
(3)
(2)
(1)

Hepatitis C Virus
N
(3)
(2)
(2)
(2)
(5)
(3)
(2)
(5)
(2)
(1)
(1)
(2)
(1)

N= number of studies reviewed * Highlighted cells represent studied outcomes with varied result

112

APPENDIX B.
CHARACTERISTICS OF SINGLETON PREGNANCIES INFECTED WITH HEPATITIS B OR C VIRUS,
SOUTH CAROLINA, 2004-2011
Table B.1 Characteristics of singleton pregnancies infected with Hepatitis B or C virus
compared to non-infected pregnancies, South Carolina, 2004-2011
HCV +
number (%)
CHESS
BC
(n=623)
(n=283)
Age in years, median (range) 28 (15 - 44) 26 (15 - 42)
< 20 years
37 ( 6)
31 (11)
20-29 years
343 (55)
159 (56)
≥ 30 years
243 (39)
93 (33)
Race/ethnicity
Non-Hispanic White
479 (77)
164 (58)
Non-Hispanic Black
105 (17)
82 (29)
Hispanic
22 ( 4)
21 ( 7)
Other
16 ( 3)
15 ( 5)
Maternal education
< High school
204 (33)
71 (25)
High school
206 (33)
81 (29)
Beyond high school
211 (34)
128 (45)
Did mother use WIC
Yes
434 (70)
151 (53)
No
173 (28)
123 (43)
Unknown
16 ( 3)
9 ( 3)
Payment source for delivery
Medicaid
473 (76)
148 (52)
Private Insurance
95 (15)
97 (34)
Self-pay
29 ( 5)
18 ( 6)
Other
25 ( 4)
15 ( 5)
Did mother smoke during
pregnancy
Yes
342 (55)
74 (26)
No
281 (45)
209 (74)
STI present during
pregnancyd?
Yes
69 (11)
19 ( 7)
No
554 (89)
264 (93)

113

HBV+
number (%)
CHESS
BCa
(n=647)
(n = 266)
28 (15 - 46) 27 (16 - 43)
51 ( 8)
14 ( 5)
339 (52)
150 (56)
257 (40)
102 (38)

Non infected
number (%)
(n = 436,389) P-valueb
26 (15 - 49)
<0.0001c
57388 (13)
<0.0001
250132 (57)
128869 (30)

122 (19)
286 (44)
36 ( 6)
197 (30)

79 (30)
112 (42)
27 (10)
46 (17)

240905 (55)
143767 (33)
41164 ( 9)
9121 ( 2)

<0.0001

192 (30)
186 (29)
263 (41)

68 (26)
76 (29)
121 (45)

100545 (23)
112169 (26)
222319 (51)

<0.0001

371 (57)
265 (41)
11 ( 2)

143 (54)
111 (42)
12 ( 5)

234108 (54)
194816 (45)
7465 ( 2)

<0.0001

352 (54)
200 (31)
61 ( 9)
29 ( 4)

149 (56)
58 (22)
27 (10)
27 (10)

216579 (50)
162793 (37)
28608 ( 7)
23881 ( 5)

<0.0001

58 ( 9)
588 (91)

46 (17)
219 (82)

56283 (13)
379845 (87)

<0.0001

75 (12)
572 (88)

31 (12)
235 (88)

30546 ( 7)
405843 (93)

<0.0001

Table B.1 Characteristics of singleton pregnancies infected with Hepatitis B or C virus
compared to non-infected pregnancies, South Carolina, 2004-2011 (cont’d.)
HCV +
number (%)
CHESS
BC
(n=623)
(n=283)
Parity
Nulliparous
Multiparous
History of alcohol abusee
Yes
No
History of drug usee
No
Yes
Primary route of drug use
Injection
/intramuscular
Other
BMI pre-pregnancy,
kg/m2
Underweight
Normal weight
Overweight
Obese
Gestational weight gaing
Adequate
Inadequate
Excessive
Missing
Previous adverse
outcomeh
No
Yes
Risk factors present in
pregnancy
No
Yes
APCU indexi
Inadequate
Intermediate
Adequate
Adequate plus
Unknown

HBV+
number (%)
CHESS
BCa
(n=647)
(n = 266)

Non infected
number (%)
(n = 436,389) P-valueb

158 (25)
465 (75)

120 (42)
163 (58)

207 (32)
439 (68)

82 (31)
184 (69)

182088 (42)
254201 (58)

<0.0001

108 (17)
515 (83)

12 ( 4)
271 (96)

21 ( 3)
626 (97)

13 ( 5)
253 (95)

7123 ( 2)
429266 (98)

<0.0001

394 (63)
229 (37)

266 (94)
17 ( 6)

631 (98)
16 ( 2)

254 (95)
12 ( 5)

427210 (98)
9179 ( 2)

<0.0001

79 (34)

4 (24)

0

1 ( 8)

482 ( 5)

<0.0001f

150 (68)

27 (76)

16 (100)

11 ( 92)

8697 (95)

36 ( 6)
272 (44)
158 (25)
143 (23)

10 ( 4)
123 (43)
73 (26)
74 (26)

37 ( 6)
275 (43)
145 (22)
180 (28)

15 ( 6)
105 (39)
63 (24)
79 (30)

18526 ( 4)
180693 (41)
107923 (25)
120239 (28)

0.234

126 (20)
209 (34)
197 (32)
91 (15)

58 (20)
78 (28)
100 (35)
47 (17)

160 (25)
195 (30)
203 (31)
89 (14)

64 (24)
80 (30)
88 (33)
34 (13)

100113 (23)
108535 (25)
160718 (37)
67023 (15)

<0.0001

533 (86)
90 (14)

253 (89)
30 (11)

567 (88)
80 (12)

235 (88)
31 (12)

398887 (91)
37502 ( 9)

<0.0001

408 (65)
215 (35)

214 (76)
69 (24)

452 (70)
195 (30)

194 (73)
72 (27)

329348 (75)
107041 (25)

<0.0001

224 (36)
51 ( 8)
118 (19)
226 (36)
4 (<1)

74 (26)
20 ( 7)
80 (28)
106 (37)
3 ( 1)

162 (25)
49 ( 8)
178 (28)
250 (39)
8 ( 1)

85 (32)
19 ( 7)
54 (20)
104 (39)
4 ( 2)

87457 (20)
31960 ( 7)
124432 (29)
188974 (43)
3566 (<1)

<0.0001

CHESS=South Carolina Health Electronic Surveillance System; BC = birth certificate (registry) data; HBV= hepatitis B
virus; HCV=hepatitis C virus, BMI=body mass index; STI= sexually transmitted infections;
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Characteristics of singleton pregnancies infected with Hepatitis B or C virus, South
Carolina, 2004-2011 (cont’d)
WIC=women, infant and children nutrition program, APCU= adequacy of prenatal care utilization.
a
These include 37 pregnancies confirmed in CHESS as acute HBV cases.
b
Pearson Chi-square test
c
Kruskall Wallis test
d
STI infections include presence of either chlamydia, gonorrhea, syphilis or genital herpes infection for that pregnancy
e
Data from Department of drug, alcohol and other drugs. Indicates if patient has received treatment services for drug or
alcohol addiction
f
Fisher exact test
g
According to the Institute of Medicine guidelines
h
Adequacy of prenatal care utilization index as defined by Kotelchuck (1994)

115

APPENDIX C.
SAS OUTPUT FREQUENCIES FOR PREGNANCY OUTCOMES BY HEPATITIS B OR C INFECTION
STATUS AT THE TIME OF A SUBSEQUENT PREGNANCY

SAS output frequencies
Hepatitis C Cases

Hepatitis B Cases

newgroup_hcv
No disease
Newly diagnosed
Chronic carriers
Total

Small for gestational age
No
Yes
Total
84947
8610
93557
103
21
124
129
19
148
85179
8650
93829

newgroup_hcv
No disease
Newly diagnosed
Chronic carriers
Total

Small for gestational age
No
Yes
Total
84947
8610
93557
52
11
63
151
16
167
85150
8637
93787

newgroup_hcv
No disease
Newly diagnosed
Chronic carriers
Total

Low birth weight
No
Yes
Total
86871
6708
93579
102
22
124
135
13
148
87108
6743
93851

newgroup_hcv
No disease
Newly diagnosed
Chronic carriers
Total

Low birth weight
No
Yes
Total
86871
6708
93579
57
6
63
156
11
167
87084
6725
93809

Preterm
Yes
Total
84533
9051
93584
104
20
124
132
16
148
84769
9087
93856

newgroup_hbv
No disease
Newly diagnosed
Chronic carriers
Total

No

NICU
Yes
Total
89214
4370
93584
114
10
124
139
9
148
89467
4389
93856

newgroup_hbv
No disease
Newly diagnosed
Chronic carriers
Total

No

newgroup_hcv
No disease
Newly diagnosed
Chronic carriers
Total

No

newgroup_hcv
No disease
Newly diagnosed
Chronic carriers
Total

No

116

Preterm
Yes
Total
84533
9051
93584
54
9
63
153
14
167
84740
9074
93814
NICU
Yes
89214
57
156
89427

4370
6
11
4387

Total
93584
63
167
93814

APPENDIX D.
ASSESSMENT OF SELECTION BIAS
Table D.1 Comparison of maternal characteristics between all prospectively observed women
with singleton pregnancies, all women with subsequent pregnancies and study sample at the time
of a subsequent pregnancy, South Carolina, 2004-2011

Maternal characteristic
Age at delivery in years,
median (range)
<20 years
20-29 years
>=30 years
Race/Ethnicity
Hispanic
Non-Hispanic White
Non-Hispanic Black
Other
Education
< High school
High school
Beyond High school
WIC usage
No
Yes
Payment source for delivery
Medicaid
Private Insurance
Self-pay
Other
Smoking
No
Yes
Any STI present?
No
Yes

All Women
(N=438,208)

Women with
subsequent
pregnancies
(N=211,457)

Study sample at
time of subsequent
pregnancy
(N= 95,291)

26 (15 - 49)
57521 (13)
251113 (57)
129544 (30)

25 (15 - 49)
28838 (14)
130370 (62)
52124 (25)

26 (15 - 49)
6581 ( 7)
58766 (62)
29944 (31)

41268 ( 9)
241736 (55)
144342 (33)
9391 ( 2)

19133 ( 9)
114466 (54)
73603 (35)
3494 ( 2)

8701 ( 9)
52553 (55)
32236 (34)
1605 ( 2)

101069 (23)
112708 (26)
223033 (51)

56384 (27)
55287 (26)
98964 (47)

22081 (23)
25133 (26)
47755 (50)

195476 (45)
235190 (54)

92998 (44)
114660 (54)

44718 (47)
48921 (51)

217681 (50)
163240 (37)
28739 ( 7)
23974 ( 5)

113223 (54)
73949 (35)
14007 ( 7)
7980 ( 4)

49832 (52)
35433 (37)
5973 ( 6)
3404 ( 4)

381120 (87)
56795 (13)

182752 (86)
28452 (13)

82639 (87)
12585 (13)

407439 (93)
30739 ( 7)

195637 (93)
15695 ( 7)

88555 (93)
6736 ( 7)
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Table D.1 Comparison of maternal characteristics between all prospectively observed
pregnancies, women with subsequent pregnancies and study sample at time of subsequent
pregnancy, South Carolina, 2004-2011 (cont’d.)

Maternal characteristic
Pre-pregnancy BMI
Underweight, BMI<18.5
Normal weight, 18.5<=BMI<25
Overweight, 25<=BMI<30
Obese, BMI>=30
Previous adverse pregnancy outcome
No
Yes
Risk factors present in pregnancy
No
Yes
History of alcohol use
No
Yes
History of drug use
No
Yes
Adequacy of prenatal care
Missing
Inadequate
Intermediate
Adequate
Adequate plus

All Women
(N=438,208)

Women with
subsequent
pregnancies
(N=211,457)

Study sample at
time of
subsequent
pregnancy
(N= 95,291)

18623 ( 4)
181460 (41)
108349 (25)
120707 (28)

9232 ( 4)
87672 (41)
52034 (25)
57965 (27)

3620 ( 4)
37148 (39)
24063 (25)
28350 (30)

400449 (91)
37729 ( 9)

192036 (91)
19296 ( 9)

85186 (89)
10105 (11)

330594 (75)
107584 (25)

158170 (75)
53162 (25)

64925 (68)
30366 (32)

430905 (98)
7273 ( 2)

207415 (98)
3917 ( 2)

93586 (98)
1705 ( 2)

428730 (98)
9448 ( 2)

205557 (97)
5775 ( 3)

92804 (97)
2487 ( 3)

3584 (<1)
87996 (20)
32098 ( 7)
124854 (28)
189646 (43)

1648 (<1)
45407 (21)
15601 ( 7)
60105 (28)
88571 (42)

549 (<1)
20468 (21)
6679 ( 7)
27955 (29)
39640 (42)

*Percentages may not equal to 100 because of rounding.
BMI=body mass index; STI= sexually transmitted infections; WIC=women, infant and children nutrition
program.
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